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Earlier detection of tumour responses to treatment would facilitate modification 
of treatment regimens and reduce unnecessary side effects and the costs of ineffective 
therapy. Anatomical changes following treatment are often slow to manifest and are 
occasionally misleading. Molecular imaging targeting dysregulated metabolic 
pathways in tumours can facilitate earlier detection of treatment response. The aim of 
this study was to directly compare two metabolic imaging techniques that measure 
different parts of glycolysis, 2-([18F]fluoro)-2-deoxy-D-glucose positron emission 
tomography ([18F]FDG-PET) and hyperpolarised [1-13C]pyruvate magnetic resonance 
imaging), for the purpose of detecting early responses to treatment in mouse models 
of cancer.  
Two mouse models of lymphoma, subcutaneous EL4 tumours and Eμ-Myc 
transgenic mice, were treated with etoposide and cyclophosphamide, respectively. In 
EL4 tumours 24 h after treatment there was a significant reduction in [18F]FDG uptake 
with no significant change in the hyperpolarised [1-13C]lactate/[1-13]Cpyruvate ratio. 
While treatment resulted in significant decreases in glucose transporter expression, 
there were variable amounts of cell death before and after treatment, potentially 
explaining this discrepancy. In Eμ-Myc mice, reductions of both [18F]FDG uptake and 
the [1-13C]lactate/[1-13C]pyruvate ratio were observed after treatment. However, the 
decreases in [18F]FDG uptake in cervical tumours were partially masked by high 
uptake in surrounding tissues demonstrating the benefit of improved specificity of 
hyperpolarised [1-13C]pyruvate for detecting the Warburg effect. 
In two xenograft models of human colorectal and breast adenocarcinoma, a 
large reduction in hyperpolarised [1-13C]lactate/[1-13C]pyruvate ratio was observed in 
all tumours 24 hours after treatment with a TRAIL agonist. However, despite treatment 
inducing widespread apoptosis and long-term remission, [18F]FDG-PET largely failed 
to detect a response.  Measurements of [18F]FDG uptake in disaggregated tumour 
cells that had been sorted by fluorescence-activated cell sorting demonstrated that 
inflammatory infiltration or activation was not responsible for failure to detect a 
response to treatment with [18F]FDG. Furthermore,  [1,6 13C2]glucose infusions into 
tumour bearing mice demonstrated that tumour uptake of [18F]FDG after treatment 
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Cancer is the second most common cause of death worldwide and, despite the 
significant resources that have been devoted to research and clinical oncology, it is 
still the cause of one in four deaths in the UK1, 2. Cancer is a heterogeneous group of 
diseases characterised by dysregulated cell proliferation that may, when combined 
with an acquired invasive phenotype, spread into surrounding tissues and metastasise 
to distant sites. Cancers can broadly be categorised by tissue of origin, each a distinct 
disease with its own risk factors, epidemiology, pattern of disease, treatment and 
prognosis. However, all cancers share the common pathogenesis of genetic mutations 
in the signalling pathways that control proliferation and apoptosis, normal processes 
that are required for development and maintenance of tissues throughout the lifetime 
of multi-cellular organisms3.  
DNA mutation results from errors of replication and damage to DNA. The 
majority of DNA damage arises as a result of endogenous processes, most frequently 
oxidative damage from reactive oxygen species (ROS), but a large number of other 
naturally generated chemicals also cause a myriad of DNA aberrations4. Endogenous 
DNA damage is mostly unavoidable but humans are also exposed to a large number 
of exogenous mutagens that not only add to the overall mutational burden but can 
disproportionately promote tumourigenesis by causing specific mutations at 
susceptible points in the genome. For example, aflatoxin B1 exposure strongly 
predisposes to development of hepatocellular carcinoma by causing a codon R249S 
substitution in TP53, the most frequently mutated gene in human cancer5. Tobacco 
smoking, to which over one-fifth of cancers are attributed, can increase the number of 
mutations per cell per year by up to 1506. Furthermore, benzo[a]pyrene, a carcinogen 
in cigarette smoke, forms adducts at codons 157, 248 and 273 in TP53, mutations 
 3	
seen in a majority of smoking-induced lung cancers7. DNA damage events are 
estimated at 104 - 105 lesions per day per cell. However, very efficient mechanisms 
prevent the propagation of mutations by repair or activation of cellular senescence or 
apoptosis, reducing the rate of somatic mutations permanently fixed in the genome to 
<1 per cell per day8-10.  
 The majority of mutations do not change gene expression and have no cellular 
effects but, as a result of accelerated Darwinian evolution, mutations that increase 
survival and proliferation accumulate over time, predisposing to the development of 
cancer. Theoretically, cancer cells can result from mutations in any component of the 
signalling pathways that control proliferation. In reality, a small subset of “driver” 
mutations in oncogenes and tumour suppressor genes of select pathways are mutated 
with high frequency and it is generally believed that between one and ten mutated 
“drivers” are required for the emergence of most tumours11. However, mutational 
burden and “driver mutations” occur at cancer-associated frequencies in over a 
quarter of normal cells, so clearly they aren’t the only determinant of malignancy and 
one of the biggest challenges facing cancer biology is to differentiate the driver 
mutations from the noise12. Cancer genomes are enormously diverse, with 1000-fold 
differences existing in the number of mutations across both different cancer types and 
cancers originating from the same tissue type13-15. The types of mutation range from 
base substitutions, insertions, deletions, amplifications and chromosomal 
rearrangements to copy number variations and these typically occur at increasing 
frequencies as cancers evolve16. Sequence variations are often accompanied by 
epigenetic changes that include DNA methylation, histone modification and chromatin 
changes that can further influence gene expression.  
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  Signalling pathway mutations result in cancer cells being able to proliferate 
independently of normal growth factor signalling. Similar mechanisms can cause the 
failure of inhibitory growth signals to prevent proliferation and can even be subverted 
to promote the acquisition of an invasive and metastatic phenotype17. In contrast to 
normal cells, tumour cells can undergo unlimited cycles of growth and division. The 
ends of chromosomes are protected by telomeres, lengths of hexanucleotide repeats 
that shorten with each round of cell division, and cells become senescent once these 
are lost. Tumours are able to extend the lengths of telomeres, usually by expressing 
the enzyme telomerase, and thus avoid the normal limitations of cell division. 
Furthermore, inhibition of normal cell cycle checkpoint controls means that DNA 
damage, including telomere shortening, does not result in senescence or apoptosis 
and is instead propagated to daughter cells, accelerating the accumulation of 
mutations and genomic instability17.  
 Whilst dysregulated proliferation is the key feature of tumour cells, virtually 
every aspect of intracellular and extracellular signalling is hijacked to overcome the 
barriers to macroscopic tumour formation. Like any cell, tumour cells require a supply 
of nutrients to survive and therefore angiogenesis is a key requirement for tumour size 
to progress beyond 1 – 2 mm318. Tumours secrete several factors, notably vascular 
endothelial growth factor (VEGF) and members of the angiopoietin family, that 
promote new blood vessels to form primarily by invasion and proliferation of 
endothelial cells from surrounding stroma18. Vessels may also be formed by tumour 
cells themselves in a process termed vascular mimicry. In contrast to normal capillary 
beds, tumour blood vessels are often fragile, tortuous, form arterio-venous shunts or 
blind-ending vessels and may exhibit sluggish or intermittent blood flow. Tumours also 
tend to outgrow their blood supply leading to zones of necrosis. 
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Figure 1.1. Components of the tumour microenvironment. Tumour cells (green) 
interact with and corrupt a range of different cell types. Disordered angiogenesis and 
dysregulated metabolism contribute to a hypoxic and acidic interstitial space. *Other 
immune cells include dendritic cells, myeloid-derived stem cells, natural killer T cells 
and tumour associated neutrophils. Abbreviations: IL – interleukin; PDGF – platelet-
derived growth factor; MCP – monocyte chemoattractant protein; TNF – tumour 
necrosis factor; VEGF – vascular endothelial growth factor; FGF – fibroblast growth 
factor; EGF – epidermal growth factor; COX – cyclo-oxygenase; MMP- matrix 
metalloproteinase; CCL – chemokine ligand; LN – laminin.  
 
The role of the immune system in cancer progression has long been recognised 
from observations of accelerated tumour growth in immune-suppressed mice and the 
propensity of tumours to arise at sites of chronic inflammation. Immune cells initially 
recognise tumour cells as ‘non-self’ and attempt to eliminate them. Certain immune 
cells have particular anti-tumour effects. For example, high levels of CD4+ T helper 1, 
cytotoxic CD8+ memory T cells and natural killer T cells slow growth and improve 
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prognosis. However, immune cells can also be converted to play, in combination with 
other cells - notably fibroblasts - specific roles in supporting tumour development by 
secreting a range of growth factors, chemokines, metabolic substrates and matrix 
remodelling enzymes that promote growth, angiogenesis, invasion and metastasis 
(Figure 1.1). The combination of tumour cells, recruited host cells and abnormal 
vasculature results in the formation of a self-regulating organ with a unique 
microenvironment and the emergence of the hallmarks of cancer (Figure 1.2)19.  
 
Figure 1.2. The hallmarks of cancer. Adapted from Hanahan & Weinberg 201119. 
 
1.2. Tumour Metabolism 
 Aberrant nutrient uptake and subsequent metabolism is a feature of malignant 
tumours that results from the increased demand for the synthesis of proteins, nucleic 
acids, fatty acids and other macromolecules required for increased growth and 
proliferation. In the revised Hallmarks of Cancer (2011), metabolic reprogramming was 
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included as an “emerging hallmark”, a slightly bizarre classification given that 
metabolic reprogramming of tumours was first described nearly half a century prior to 
the discovery of the first proto-oncogene, SRC19, 20. In 1924 Otto Warburg observed 
that tumour cells preferentially metabolised glucose to lactate in the presence of 
normoxia instead of utilising the TCA cycle21. Warburg concluded that cancer was 
caused by mitochondrial dysfunction and while we now know that to be largely untrue, 
the Warburg Effect, or aerobic glycolysis, is observed in most tumours. In terms of 
bioenergetics, the Warburg Effect is highly inefficient, producing only two molecules 
of ATP per molecule of glucose versus approximately thirty ATP molecules if the TCA 
cycle and oxidative phosphorylation are utilised22. Consequently, tumours often 
consume glucose and produce lactate in large quantities, the latter being used as a 
substrate for the TCA cycle or exported from the cell via monocarboxylate 
transporters23. It is possible that the switch to aerobic glycolysis is simply a response 
to the fluctuating supply of oxygen from a disordered blood supply, or alternatively that 
it confers a proliferative advantage. Pyruvate kinase (PK) catalyses the conversion of 
phosphoenolpyruvate to pyruvate in the last step of glycolysis. The predominant 
isoform of PK found in tumours is PKM2, which exists in two forms – a dimer with low 
affinity for phosphoenolpyruvate and a tetramer with high affinity and high enzymatic 
activity. Predominance of the dimeric state results in an accumulation of upstream 
metabolites that can then enter other pathways including the pentose phosphate 
pathway (PPP), the hexosamine pathway, the serine synthesis pathway and 
glycogenesis, the products of which are essential for proliferation24, 25. As well as 
producing ribose-5-phosphate, required for nucleic acid synthesis, the PPP is also a 
key source of NADPH and reduced glutathione, required to restore the redox balance 
that is disrupted by increased generation of ROS in tumours26. 
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 As well as their importance in the generation of ATP, TCA cycle metabolites 
are precursors for numerous macromolecules including lipids. Almost constant 
intracellular levels of TCA cycle metabolites are maintained by rapid replenishment, 
predominantly from pyruvate and glutamine. Pyruvate can enter the TCA cycle via 
acetyl-CoA or be carboxylated to oxaloacetate and both of these pathways can be 
upregulated in tumours23, 27. Glutamine uptake is increased in many cancer cell lines 
and some tumours27-29. Glutamine contributes to TCA cycle anaplerosis predominantly 
by conversion to glutamate, in the reaction catalysed by glutaminase, and subsequent 
deamination to generate α-ketoglutarate. It also serves as an important nitrogen 




 Mutation of metabolic enzymes leading to a change in function and subsequent 
accumulation of metabolites at supra-physiological concentrations has been proposed 
recently as a trigger of tumourigenesis, as Warburg suggested nearly a century ago. 
 Loss of function mutations in fumarate hydratase (FH) results in accumulation 
of fumarate and is seen in a subset of hereditary renal cancers. Loss of succinate 
dehydrogenase (SDH) function and subsequent accumulation of succinate is 
associated with various tumours including neuroendocrine, renal, and gastrointestinal 
stromal tumours. Both fumarate and succinate are competitive inhibitors of the α-
ketoglutarate (α-KG)-dependent dioxygenases, which include the hypoxia inducible 
factor (HIF) prolyl hydroxylases, ten-eleven translocation proteins (TETs) and the 
histone lysine demethylases. The consequent stabilisation of HIF, even in the 
presence of oxygen, and the methylation changes that result from the accumulation of 
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these metabolites have been proposed as a mechanism for tumourigenesis. 
Additionally, fumarate upregulates the mTOR/HIF1α pathway and the NF-ΚB pathway, 
both frequently stimulated in cancers31, 32. 
 Isocitrate dehydrogenase (IDH)-1 and IDH2, the cytosolic and mitochondrial 
form of the enzyme respectively, are mutated in a majority of gliomas and some acute 
myeloid leukaemias33, 34. Wild-type isocitrate dehydrogenase (IDH) catalyses 
isocitrate decarboxylation to α-ketoglutarate (α-KG) but the most common mutation of 
IDH leads to a neomorphic function where it reduces α-KG to 2-hydroxyglutarate (2-
HG). In normal tissues 2-HG is kept at very low levels but in IDH-mutant tissues its 
concentration rises to millimolar (mM) levels. By inhibition of α-KG-dependent 
dioxygenases, as seen with fumarate and succinate accumulation, 2-HG induces 
widespread methylation changes and HIF stabilisation35, 36. 
 
1.2.2. Control of metabolism 
 The control of metabolism in tumours is multi-faceted, complex and 
incompletely understood. The supply of metabolites is dependent on highly variable 
factors in tumours including proximity to blood vessels, viability of those blood vessels 
and the extracellular microenvironment, all of which are heterogeneous in a solid 
tumour. A degree of control is exerted on metabolic enzymes by the abundance of the 
substrate, co-factors, product and pH. Furthermore, the expression of enzymes of the 
key metabolic pathways is partly regulated by signalling pathways that also control 
proliferation and contain some of the most commonly mutated genes in cancer. Some 
of the common mutations that influence glucose metabolism are shown in Figure 1.3. 
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Figure 1.3. Glycolysis and some of the major regulators. Black – metabolic 
intermediates; red – enzymes; light blue – cofactors, by-products and redox 
substrates/products; orange – expression regulation: arrows indicate upregulation 
while flat-ends indicate down-regulation by the wild-type gene.  
  
Mutated in >50% of human cancers, TP53 helps maintain genomic stability and 
regulates the expression of numerous genes responsible for cell cycle control, DNA 
repair and apoptosis as well as having multiple effects on cellular metabolism. By 
affecting multiple overlapping pathways, wild-type TP53 can both promote and down-
regulate glycolysis although the overall picture appears to be one of inhibition of 
glycolysis and promotion of oxidative phosphorylation. The picture is complicated 
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further by TP53 mutation resulting in both loss of wild-type function and gain of 
oncogenic function in cancers37. For example, wild-type TP53 decreases expression 
of glucose transporters (GLUT) 1, 3 and 4, and phosphoglycerate mutase while 
inducing TP53-induced glycolysis and apoptosis regulator (TIGAR), all of which 
reduces glycolytic flux. TIGAR has the effect of reducing fructose-2,6-bisphosphate 
levels, which results in inhibition of phosphofructokinase and directs flux towards the 
PPP. However, mutant TP53 upregulates hexokinase 2 expression and promotes 
translocation of GLUT1 to the cell membrane38, 39. Downstream, TP53 decreases 
pyruvate dehydrogenase kinase expression, increasing pyruvate dehydrogenase 
activity and conversion of pyruvate to acetyl-CoA40. Oxidative phosphorylation is 
further elevated by wild-type TP53 upregulation of synthesis of cytochrome c oxidase 
2 (SCO2) synthesis, which is required for assembly of complex IV of the electron 
transport chain41. 
Aberrant PI3K / AKT / mTOR pathway signalling is common in tumours, often 
occurring as a result of over-expression of PI3K, inactivation of PTEN, RAS mutation 
or growth factor receptor mutation. Activation of AKT (protein kinase B) can modulate 
expression of glycolytic transporters and enzymes both directly and indirectly by 
regulating a range of transcription factors, e.g. the forkhead box (FOX) family, and via 
activation of mammalian target of rapamycin (mTOR)25. One of the key actions of 
mTOR is to up-regulate hypoxia-inducible factor (HIF), even in the absence of hypoxia. 
HIF1 upregulates transcription of most of the glycolytic enzymes and also activates 
the pyruvate dehydrogenase kinases (PDKs), inhibiting pyruvate dehydrogenase and 
reducing pyruvate flux into the TCA cycle25, 42, 43. 
The transcription factor MYC is estimated to control the expression of around 
15% of human genes in normal cells. MYC lies at the crossroads of several key 
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signalling pathways, and although the protein itself is rarely mutated, as a result of 
upstream mutations it is over-expressed in most human cancers. Rather than causing 
transcription of a new set of genes, it has recently become apparent that MYC 
accumulates at promoters across the genome, its abnormal expression in tumour cells 
deregulating transcription of multiple sets of genes44, 45. In addition to its role 
controlling proliferation and apoptosis, MYC exerts effects on angiogenesis, invasion, 
stromal remodelling and inflammation whilst also having a direct regulatory role in 
metabolism. It is thought that MYC induces transcription of virtually all glycolytic genes 
including lactate dehydrogenase A (LDH-A) and PDK1, thus promoting the production 
of lactate from glycolysis25, 46, 47. 
 
1.3. Cancer Imaging 
In November 1895 the field of medical imaging was born when, quite by 
accident, Wilhelm Röntgen imaged the bones of his own hand, and shortly afterwards 
published the first x-ray of his wife’s hand, whilst experimenting with a cathode ray 
tube. Less than a year later x-rays were first applied in cancer imaging when Franz 
König revealed a sarcoma of the tibia48. The invention of x-ray computed tomography 
(CT) in 1971 and magnetic resonance imaging (MRI) in 1973 revolutionised oncology 
as, for the first time, three-dimensional, whole body imaging permitted tumours and 
their metastases to be visualised49, 50. These techniques rapidly became, and remain, 
essential tools for cancer diagnosis, staging and monitoring response to treatment. 
 
1.3.1. Imaging response to treatment 
 For the majority of solid tumours measurements of tumour size using CT and/or 
MRI is the best biomarker of response in routine clinical practice. Comparing before- 
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and after-treatment imaging allows patients to be classified as having a complete 
response, partial response, stable disease or progressive disease based on criteria 
such as the Response Evaluation Criteria in Solid Tumours (RECIST 1.1)51. However, 
it is evident that anatomical imaging has its limitations, particularly when assessing 
response to treatment. The vast heterogeneity of tumour genotypes and phenotypes 
means that, whilst appearing anatomically and morphologically similar, tumours may 
behave quite differently, including in their responses to treatment. Anatomical changes 
following treatment are usually delayed, repeat scans typically being performed at 
least 6 weeks after commencing therapy52. Furthermore, there are now several 
examples, particularly with the introduction of targeted therapies that may be cytostatic 
rather than cytotoxic, where no improvements were detectable by the RECIST criteria 
but significant clinical efficacy was demonstrated53. There are also regular instances 
where size changes are difficult to interpret, for example distinguishing tumour from 
fibrotic tissue following radiotherapy or chemotherapy. Pseudoprogression, whereby 
tumours initially increase in size in response to effective treatment, is also an 
increasingly common problem following the introduction of immunotherapy, the 
highest rates (up to 8.3%) being reported in melanoma patients treated with the anti 
PD-1 antibody nivolumab54-56.  
 Molecular imaging techniques that report on aspects of tissue biochemistry 
have the potential to address some of the limitations of anatomical imaging. Following 
treatment biochemical changes occur prior to changes in tumour volume and therefore 
molecular imaging could be used to detect treatment response at earlier time points 
than is currently possible57. With the pool of targeted drug therapies slowly growing, 
early detection of treatment efficacy would allow patients to be rapidly switched to 
more effective therapeutics as necessary and avoid prolonged use of therapies that 
 14	
are ineffective, costly and potentially toxic. The next sections will outline the principles 
of the molecular imaging techniques used in this project. 
 
1.4. Positron Emission Tomography (PET) 
 Positron emission tomography is a nuclear medicine technique detecting 
radionuclides that decay by positron emission. Positron emission generates two high-
energy photons capable of travelling through body tissues and can be detected by a 
PET scanner containing a ring of detectors surrounding the patient that generate an 
electrical signal in response to photon detection. After correction for a number of 
factors the signals can be reconstructed into a 3D volume where the signal intensity 
of each voxel is proportional to the amount of radionuclide present. Thus, when 
radionuclides are used to label biologically relevant molecules, the spatial distribution 
of their concentration can be quantitatively mapped58.   
 
1.4.1. Principles of PET 
 Nuclei with an unequal number of protons or neutrons are unstable and prone 
to radioactive decay. Nuclei with an excess of protons may decay by positron emission 
(β+ decay), whereby a proton is converted into a neutron and a positron (β+ - the 
antiparticle of an electron with the same mass but opposite charge) and an electron 
neutrino (νe) are ejected from the nucleus. Fluorine-18 (18F) decays to stable oxygen-
18: 
F9
18          O 8
18 + β+ + νe 
 Following ejection from the nucleus, the positron follows a tortuous course while 
rapidly losing kinetic energy by Coulomb interactions with electrons. Upon reaching 
thermal energy, the positron combines with an electron and annihilates, 
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simultaneously emitting two gamma photons in opposite directions (very close to 180º 
apart). As the positron is almost at rest when annihilation occurs, the energy emitted 
is proportional to the mass of the positron and the electron it annihilates with and 
equates to two 511 keV gamma photons which are able to pass through tissues to be 
detected externally. A line of response drawn between simultaneously detected 
photons (<18 ns apart) passes through the point of annihilation (Figure 1.4). To 
determine the point along the line of response where an annihilation event occurred, 
computed tomography algorithms infer the concentration of radioactivity in each voxel 
based on measurements at different angles through the object, a process that typically 
requires >106 coincident events for each PET scan. In modern clinical scanners time-
of-flight measurements can be used to localise further the annihilation event along the 
line of response58. Numerous other factors are corrected for during image 
reconstruction, including decay, scatter, dead time, attenuation and random events. 
Most modern scanners also incorporate a computed tomography (CT) scan, which is 
used for anatomical co-registration and attenuation correction59. 
 
1.4.2. 2-([18F]fluoro)-2-deoxy-D-glucose ([18F]FDG)-PET 
 18F is by far the most widely used PET radionuclide due to its favourable half-
life (Table 1.1), decay to a stable product and ability to form strong covalent or ionic 
bonds with most elements, especially carbon60. [18F]FDG, a glucose molecule in which 
the 2’ hydroxyl group has been substituted with 18F, was the first tracer to be used in 
humans and remains the most common tracer in clinical use today. The metabolism 
of [18F]FDG closely mimics the initial metabolism of glucose. After injection into the 
circulation [18F]FDG enters cells via facilitative glucose transporters (GLUTs) and is 
renally excreted. Upon entering a cell [18F]FDG is phosphorylated to [18F]FDG-6-
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phosphate which cannot be isomerised by glucose-6-phosphate isomerase and 
therefore does not undergo further steps of glycolysis. [18F]FDG-6-phosphate is 
trapped intracellularly and due to the low rate of de-phosphorylation in most cells, 
gradual accumulation of 18F label in glucose-avid tissues can be visualised as areas 
of increased uptake on PET scans. PET is an extremely sensitive technique and 
tracers are administered in nanomole quantities, meaning that [18F]FDG does not have 
an inhibitory effect on metabolism61.   







11C 20.3 0.96 1.1 1 
13N 9.97 1.19 1.4 1 
15O 2.03 1.70 1.5 1 
18F 109.8 0.64 1.0 0.97 
68Ga 67.72 1.90 2.9 0.89 
 Table 1.1. Commonly used PET radionuclides, their half-lives, positron energy, 
positron range in water and β+ branching fraction. The positron range is the 
distance travelled between positron emission and annihilation and is defined by the 
positron energy, determined in turn by the difference in atomic mass between the 
parent atom and daughter atom. The β+ branching fraction refers to the proportion of 
decay events that result in the emission of a β+, with electron capture being the other 
method of decay58, 62.  
  
 Most tumours are highly glycolytic and uptake of [18F]FDG has been used as a 
marker of increased glucose uptake to screen, diagnose, stage and detect response 
to treatment in cancer63. Many of the fourteen known GLUTs are over-expressed in 
various human cancers, whereas of the four mammalian isoforms of hexokinase (HK), 
the over-expression of HK2 is seen most frequently in tumours64-66. However, studies 
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attempting to correlate [18F]FDG uptake and GLUT and/or HK2 expression are 
inconsistent, suggesting the determinant of [18F]FDG uptake rate is, like so many 
aspects of biology, complex and multi-factorial67-73. 
 
Figure 1.4. The principle of positron emission tomography with 18F. 18F 
undergoes spontaneous decay to 18O, usually emitting a positron (red) and a neutrino. 
The positron travels a short distance before annihilation with an electron (yellow). This 
emits two gamma photons (blue lines) at approximately 180° with respect to each 
other. A line is drawn between photons arriving at opposite detector rings 
coincidentally (the line of response) to spatially reconstruct the annihilation event. 
 
 The advantages of [18F]FDG-PET include its high sensitivity and the capability 
of whole-body image acquisition. It is limited by the relatively low resolution that can 
be achieved in clinical scanners (~5 mm)74, lack of metabolite specificity, reporting 
only on the first two steps of glycolysis (uptake and phosphorylation) and by the high 
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background uptake from normal, glucose-avid tissues that can result in false-positive 
tumour imaging75.  
 
1.4.3. [18F]FDG-PET imaging of treatment response 
Positive correlation between [18F]FDG uptake and the number of viable tumour 
cells has been reported and [18F]FDG-PET has successfully detected treatment 
response and/or recurrence in many cancers in patients, in most cases improving on 
anatomical imaging for the determination of pathological response76-80. In certain 
cancers - notably lymphoma, oesophageal cancer and gastro-intestinal stromal 
tumours (GISTs) - the outcome of post-treatment [18F]FDG-PET imaging is used to 
inform patient management81, 82. In GISTs treated with imatinib, a BCR-ABL tyrosine 
kinase inhibitor, and lymphomas treated with cytotoxic chemotherapy, a reduction in 
[18F]FDG uptake has been observed days after initiation of therapy and months before 
changes in tumour size83, 84. Furthermore, there is an increasing body of evidence that 
suggests patients with scans that normalise rapidly after treatment have a better 
outcome, therefore earlier assessment of tumours post-treatment would be 
beneficial78, 79, 85. Interim PET-CT, after one or two cycles of chemotherapy, has 
become routine to monitor some subtypes of lymphoma86.  
However, concerns that early 18FDG-PET scans remain inaccurate prognostic 
indicators have limited its use in prediction of early treatment response. Much of this 
concern is due to the metabolic “flare” effect, a transient increase in [18F]FDG uptake 
seen after treatment. This has been largely attributed to inflammatory cell infiltration 
and activation following tumour cell death87, 88. Additionally, breast cancer patients 
responding to tamoxifen have been shown to have higher [18F]FDG uptake in the first 
two weeks after initiation of therapy relative to non-responders. This was attributed to 
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oestrogen receptor modulation by tamoxifen resulting in a transient upregulation of 
glycolysis89. 
  
1.5. Nuclear magnetic resonance and magnetic resonance imaging 
Nuclear magnetic resonance (NMR) is the phenomenon of nuclei in a magnetic 
field absorbing and emitting electromagnetic radiation, the discovery of which led to 
Felix Bloch and Edward Purcell sharing the 1952 Nobel Prize in Physics90. Nuclei that 
do not have even mass and atomic numbers, along with other elementary particles, 
e.g. electrons, possess an intrinsic angular momentum known as spin. The nuclei of 
interest here, namely 1H and 13C, are examples of spin ½ systems and in the presence 
of an external magnetic field (B0) their nuclei populate two quantized energy levels. 
Spins in the lower energy level correspond to magnetic moments that align parallel 
with B0 while spins in the higher energy level align anti-parallel with B0 (Figure 1.5)91, 
92. Spins precess around B0 at the Larmor frequency (ω0) given by:  
ω0 = ɣB0 
where ɣ is the gyromagnetic ratio, a constant for each nucleus. At thermal equilibrium 
the number of spins in the lower energy level slightly outnumber those in the higher 
energy level. The difference in energy between the two levels is given by the equation 
(h = Planck’s constant; ν = frequency):   
ΔE = hν 
 Nuclei are able to transition between energy levels if exactly ΔE is applied to 
them. In NMR this is achieved by applying a radiofrequency (RF) oscillating magnetic 
field at the resonant frequency. Nuclei absorb the energy which induces flipping 
between energy levels. Due to the slight predominance of nuclei in the lower energy 
state, the net result of an RF pulse is to increase the number of nuclei occupying the 
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higher energy state. The application of this oscillating magnetic field in the form of a 
resonant frequency pulse perpendicular to B0 flips the net magnetisation into the x-y 
plane (Figure 1.6). Precession in the x-y plane induces a voltage in a receiver coil that 
oscillates at the Larmor frequency and produces a free induction decay (FID). The FID 
is a time-domain signal comprising all of the excited frequencies. After acquisition the 
signal is digitised and Fourier transform converts the FID into a frequency domain 
signal91, 92. 
 
Figure 1.5. Energy levels of a spin ½ system (left) and spin distributions in a 
magnetic field (right). Spins align with the external magnetic field (B0) with a slight 
majority of spins in the lower energy level, parallel to B0. This results in a net 
magnetisation vector parallel to B0. 
 
Figure 1.6. Rotation of the net magnetisation vector (M0) after the application of 
a 90° pulse. At equilibrium the net magnetisation vector (red arrow) is parallel to B0 
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(left). An RF pulse along the x-axis (B1) (blue arrow) at the Larmor frequency rotates 
the net magnetisation vector in the y- – z-axis (right). The angle of rotation is 
dependent on the amplitude and duration of B1.  
 
1.5.1. Signal decay 
 After the application of an RF pulse the system gradually returns to thermal 
equilibrium in a process known as relaxation. Spin-lattice relaxation describes the 
exponential return of the net magnetisation vector toward its thermal equilibrium value. 
In quantum terms this occurs because there is a net redistribution of spins from the 
higher energy state to the lower energy state.  The spin-lattice relaxation time, T1, is 
defined as the time taken for the net magnetisation vector to return to 63% of its 
thermal equilibrium value. This occurs by transferring energy to the surrounding 
molecular environment. Spin-spin relaxation describes relaxation in the x-y plane and 
the spin-spin relaxation time, T2, is the time take for the transverse magnetisation to 
decay to 37% of its initial value. Following an RF pulse, all spins are in phase. Due to 
the interactions between spins they dephase, resulting in an exponential reduction in 
the magnetisation vector in the x-y plane. In biological tissues T2 relaxation occurs at 
a much faster rate than T1 relaxation92.  
 
1.5.2. Magnetic Resonance Imaging (MRI) 
The abundance of tissue water protons in biological tissues (approximately 60-
80 M) and the high gyromagnetic ratio of the proton permits magnetic resonance 
imaging at resolutions as high as 50 µm in in vivo pre-clinical studies93, 94. To produce 
images instead of spectra, magnetic field gradients are applied that change the 
magnetic field across an imaging plane. These gradients alter the magnetic field so 
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that spins can be localised according to their resonance frequency. Gradients can be 
applied in all three planes. Slice selection is achieved by applying a gradient 
perpendicular to the plane of interest. All nuclei in a slice experience the same change 
in magnetic field and can be selectively excited by the simultaneous application of a 
frequency-selective RF pulse. Phase encoding and frequency encoding gradients are 
used for spatial localisation in the other two dimensions92. In 1H magnetic resonance 
imaging (MRI) the different rates of T1 and T2 relaxation in different molecular 
environments are exploited to produce contrast between different tissues. Additionally, 
paramagnetic contrast agents e.g. gadolinium can be introduced that remain in certain 
fluid compartments and enhance contrast by shortening T1 and T295. 
 
1.5.3. Magnetic Resonance Spectroscopy (MRS) 
 Depending on the immediate electronic environment of the nucleus the 
resonant frequency changes by a few kHz. Therefore, nuclei in different molecules 
resonate at slightly different frequencies, an effect known as chemical shift. The 
frequency of the chemical shift can be expressed in parts per million (ppm) of the 
spectrometer operating frequency, where the chemical shift of each molecule is 
referenced to a standard92. 1H magnetic resonance spectroscopy (MRS) can 
differentiate between steady-state tissue metabolites in the millimolar range in vivo, 
but the inherent insensitivity of NMR limits the spatial and temporal resolution of scans 
to around 1 cm3 and  5 – 10 min, respectively96-98.  
 Metabolic fluxes can be studied by introduction of isotopically labelled 
substrates99. 13C represents only 1.1% of all carbon and has been used to label 
numerous substrates for in vivo studies of metabolic fluxes100. Signal-to-noise ratio 
(SNR) can be increased by using higher field strengths to increase the difference 
 23	
between spin populations and by indirect detection via spin-coupled protons. However, 
the signal is still too limited to permit imaging96.  
 
1.5.4. Dissolution Dynamic Nuclear Polarisation (DNP) 
A further transient increase in NMR signal by >104 is made possible by dynamic 
nuclear polarisation (DNP)101. Although it can in principle be used with any NMR-active 
nucleus, the majority of studies have been performed with 13C-labelled molecules 
because of their relatively long polarisation lifetime and the possibility of measuring 
metabolic fluxes with 13C-labelled cell metabolites.  In DNP the substrate to be 
polarised is mixed with a stable radical (a source of unpaired electrons). The sample 
is then cooled to ~1 K to form a solid and placed in a magnetic field, typically >3 Tesla. 
For DNP to be effective the radical must be distributed homogeneously throughout the 
sample, therefore the sample must form a glass and not crystallise. Depending on the 
substrate it may be necessary to add a solvent such as DMSO to achieve this. At ~1 
K and high magnetic field the electron spins are nearly 100% polarised. Microwave 
irradiation at the resonant frequency of the electron partly transfers the electron spin 
polarisation to the nuclei96, 101-103. The addition of gadolinium (Gd3+) ions shortens the 
electron T1 spin-lattice relaxation time and can improve sample polarisation by up to 
300%104. 
 At room temperature the nuclear T1 in the presence of the radical is very short. 
In 2003 the dissolution step was invented that allows a sample to be rapidly heated to 
room temperature. A buffered solvent, heated and pressurised to ~180 °C and 10 bar, 
flushes the sample out of the hyperpolariser101. The procedure from the start of 
dissolution to injection into a subject can be comfortably accomplished in <15s in pre-
clinical studies. Once heated to room temperature the polarisation starts to decay at a 
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rate dictated by the T1 of the nucleus. The hyperpolarisation afforded by DNP has 
permitted in vivo measurement of metabolic fluxes by spectroscopy and spectroscopic 
imaging. For example, [1-13C]pyruvate has a T1 of around 40 s at 9.4 T and >60% 
polarisation has been achieved using custom-built high-field polarisers, meaning the 
signal can last >3 min in vivo, permitting the measurement of [1-13C]lactate, 
1[13C]alanine, and 13C-bicarbonate, the immediate products of its metabolism105-108. 
 
1.6. Investigating cancer metabolism with hyperpolarised 13C-labelled 
substrates  
 Numerous hyperpolarised 13C-labelled substrates have been used in pre-
clinical studies of cancer metabolism, although limited levels of polarisation and short 
T1s in the liquid state make few clinically translatable (Table 1.2 and Figure 1.7)109. 
Owing to its position in the glycolytic pathway and favourable polarisation properties, 
[1-13C]pyruvate has been the most commonly used substrate and it has also been 
used in clinical studies110, 111. The ability to non-invasively image real-time metabolic 
fluxes has the potential to impact on many aspects of cancer management from 
screening, diagnosis and phenotyping to prognostication. However, to translate to 
routine use in clinical oncology, hyperpolarised MRI must provide novel information 
that influences clinical management. Here we will discuss the recent applications of 
hyperpolarised MRI in oncology.  
 
1.6.1. Screening, diagnosis and disease progression 
 Financial and time constraints limit population-based screening with any cross-
sectional imaging technique, let alone hyperpolarised MRI. However, it may be 
feasible for highly stratified groups such as patients with hereditary cancer syndromes, 
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especially in conjunction with pre-screening strategies based upon new, more 
sensitive and specific circulating biomarkers. Patients identified by these methods 
could then potentially undergo multi-modality molecular imaging to confirm the 
diagnosis, improve staging and identify potential therapeutic targets.  
 
Table 1.2. The properties of some hyperpolarised substrates that have been 
used in cancer studies. The numbers in parentheses after the T1 values are the field 
strengths at which these relaxation times were measured. Abbreviations: MCT – 
monocarboxylate transporter; LDH – lactate dehydrogenase; PDH – pyruvate 
dehydrogenase; ALT – alanine transaminase; IDH – isocitrate dehydrogenase; GGT 
– ɣ-glutamyltransferase. 
Metabolite T1 (s) Polarisation Measurable products Measures Refs 









[1,4-13C2]fumarate 24 (9.4 T) 26 – 35% [1,4-13C2]malate 




of  [1,4-13C2]fumarate 
to [1,4-13C2]malate 
112 













LDH and ALT 
expression 
114 





[1-13C]glutamine 31 (1 T) 34.7 ±7% [1-13C]2-hydroxyglutarate Mutant IDH expression 
116 
[5-13C]glutamine 16 (9.4 T) 5% [5-13C]glutamate Glutaminase activity, glutamine transport 
117 
[1-13C]glutamate 34 (9.4 T) 28% [1-13C]α-ketoglutarate ALT activity, pyruvate availability 
118 








ɣ-glutamyl-[1-13C]glycine 30 (9.4 T) 5.4% [1-13C]glycine GGT activity 120 
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Figure 1.7. Metabolic processes targeted with hyperpolarised 13C-labelled 
metabolites. Colour coding: pink – enzymes; yellow – hyperpolarised 13C-labelled 
substrates; green – measurable hyperpolarised 13C-labeled products; cyan –  
hyperpolarised 13C labelled substrates and measurable products (depending on the 
substrate injected). Abbreviations: ALT – alanine transaminase; ASCTs – alanine, 
serine, cysteine transporters (there are also several other transporters that can 
transport glutamine into cells); BCAT – branched-chain amino acid aminotransferase; 
CAIX – carbonic anhydrase 9; DCTs – dicarboxylate transporters; DHAR – 
dehydroascorbate reductase; GGT – ɣ-glutamyltransferase; GLDH – glutamate 
dehydrogenase; GLS – glutaminase; GLUTs – glucose transporters; GR – glutathione 
reductase; GSH – glutathione; GSSG – glutathione disulfide; IDH – isocitrate 
dehydrogenase; LDH – lactate dehydrogenase; MCTs – monocarboxylate 
transporters; PC – pyruvate carboxylase; PDH – pyruvate dehydrogenase; PPP – 




 In prostate cancer there is a requirement for new approaches to determine 
tumour aggressiveness. 30-70% of men over sixty are estimated to have prostate 
cancer but the vast majority require no treatment121. However, 30% of patients defined 
as being low-risk actually harbour higher-grade tumours that would benefit from early 
treatment122. Multi-parametric 1H MRI has As four out of five cases present with 
localised disease, imaging with hyperpolarised [1-13C]pyruvate is a potentially useful 
tool for determining the aggressiveness of these tumours123. This was illustrated in the 
first-in-man study in which, following injection of hyperpolarised [1-13C]pyruvate, an 
elevated [1-13C]lactate/[1-13C]pyruvate ratio was observed in tumour regions. in one 
patient a biopsy-proven tumour was identified by hyperpolarised imaging but not by 
multi-parametric 1H-MRI111.  
 In a study using a transgenic mouse model of prostate adenocarcinoma 
(TRAMP), co-polarisation of [1-13C]pyruvate and 13C-urea (an agent for imaging 
perfusion) showed both to be capable of differentiating high- and low-grade tumours, 
with high-grade tumours showing increased lactate labelling and reduced perfusion 
but higher vascular permeability and 13C urea washout124.   
 Pancreatic cancer has a >90% mortality within 5 years of diagnosis and survival 
prospects that are dependent on early detection and surgery123. The injection of 
hyperpolarised [1-13C]pyruvate into genetically engineered mouse models of 
pancreatic ductal adenocarcinoma showed the [1-13C]alanine/[1-13C]lactate ratio 
decreased with disease progression106. If hyperpolarised [1-13C]pyruvate can 
differentiate neoplastic lesions from inflammatory and pre-neoplastic lesions in 
patients, it could have a significant impact on patient management. 
 Similarly, hepatocellular carcinoma has a mortality rate in excess of 95%, 
making it the second most common cause of cancer mortality worldwide. However, 
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localised tumours suitable for resection or ablation have a good prognosis125. 
Differentiation of small malignant tumours from benign tumours and cirrhotic liver is 
challenging but may be aided by metabolic imaging. In hepatoma cells glutamine 
uptake is 10-30 fold greater than in normal hepatocytes126-128. The hydrolysis of 
hyperpolarised [5-13C]glutamine to [5-13C]glutamate differentiated in vivo rat 
hepatomas from normal liver117, 129. However, the short T1 and poor polarisation of [5-
13C]glutamine may ultimately limit clinical translation130.  
 
 
1.6.2. Tumour phenotyping 
 
 Metabolic phenotyping could dictate patient management and improve 
prognostication. Several new approaches to tumour metabolic phenotyping with 
hyperpolarised substrates are discussed below.  
 
1.6.2.1. Isocitrate dehydrogenase (IDH) 
 Wild-type IDH catalyses oxidative decarboxylation of isocitrate to produce α-
ketoglutarate (α-KG). As noted earlier, the most common IDH mutation promotes the 
reduction of α-KG to the oncometabolite D-2-hydroxyglutarate (2-HG)36. IDH1, the 
cytosolic isoform, is mutated in >70% of low-grade gliomas33 and non-invasive 
determination of IDH1 mutational status would change the approach to surgical 
resection. [1-13C]2-HG has been observed in tumour models in vivo following injection 
of hyperpolarised [1-13C]α-KG  and [1-13C]glutamine115, 116. Mutations in IDH1 have 
also been associated with down-regulation of PDH activity and reduced [5-




1.6.2.2. Branched-chain aminotransferase (BCAT)  
 Intracellular levels of branched-chain amino acids (BCAAs) are tightly 
controlled, with defective catabolic pathways leading to severe neurological damage 
and death if untreated. The first step in BCAA catabolism is the transfer of an α-amino 
group to α-KG catalysed by branched-chain aminotransferase (BCAT) that, under the 
control of MYC, is over-expressed in a number of cancers correlating with higher rates 
of proliferation and poorer prognosis133-135. In glioblastoma wild-type IDH promotes 
upregulation of BCAT1. Mutant IDH not only produces 2-HG and depletes the α-KG 
pool but also down-regulates BCAT1 by hypermethylation of its main promoter 
region135. Hyperpolarised α-keto-[1-13C]isocaproate (KIC) is transaminated to [1-
13C]leucine in the reversal of BCAA catabolism and leucine has been detected in EL4 
murine T-cell lymphoma tumours136. Furthermore, transported by MCTs, KIC crosses 
the blood brain barrier and is detectable in normal brain137. With favourable 
polarisation and T1 relaxation parameters, hyperpolarised KIC imaging of BCAT 
function has the potential to differentiate between high and low grade glioma and to 
phenotype other solid tumours.  
 
1.6.2.3. ɣ-glutamyl-transpeptidase (GGT) 
 GGT is bound to the outer aspect of the plasma membrane and catalyses 
degradation of extracellular glutathione to its constituent amino acids (glutamate, 
cysteine and glycine), which can then be transported intracellularly for glutathione 
synthesis. GGT is over-expressed in a variety of tumours where it may play a role in 
progression, invasion and drug resistance138. Cleavage of hyperpolarised ɣ-glutamyl-
[1-13C]glycine to [1-13C]glycine, catalysed by GGT, has been measured in normal rat 
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organs120. The next step will be to determine whether tumour over-expression of GGT 
can be detected. 
 
1.6.3. Imaging pH 
 The acidic extracellular environment of tumours results from excessive lactate 
and CO2 production from upregulated metabolic pathways, dysregulated buffering 
systems and poor perfusion (Figure 1.1)139. In addition to cancer, clinical imaging of 
pH could have implications for detection and treatment response monitoring in 
infectious, inflammatory and ischemic diseases. Injection of hyperpolarised 13C-
bicarbonate results in the production of 13CO2 in the reaction catalysed by carbonic 
anhydrase. From the H13CO3
-
/13CO2 ratio the extracellular pH and carbonic anhydrase 
activity can be determined, as demonstrated in mouse models of lymphoma and 
colorectal cancer 140, 141.  
 Several hyperpolarised probes that exhibit pH-dependent chemical shifts have 
also been proposed. 15N2-imidazole and several 15N-pyridine derivatives have been 
hyperpolarised and used in vitro, with chemical shifts of up to 60 ppm per pH unit 142, 
143. More recently [1,5-13C]zymonic acid was discovered as a contaminant of pyruvic 
acid and found to have a pH sensitive, but temperature and concentration independent, 
chemical shift of approximately 3 p.p.m. per pH unit. In vivo imaging of multiple tissues 
including tumours in rats, with nominal in-plane resolution of 3.75 mm, returned similar 
pH values to those measured by 31P MRS and a tissue pH electrode144.  
 
1.6.4. Imaging redox status 
 Oxidative stress plays a key role in carcinogenesis by directly causing DNA 
damage and cancers generally have elevated levels of reactive oxygen species (ROS) 
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which promote tumour development and resistance to therapy 145. Homeostatic 
mechanisms respond to increased ROS levels by increasing antioxidant production 
and several hyperpolarised probes have been used to monitor these regulatory 
mechanisms. For example, [1-13C]alanine has been used to measure the 
lactate/pyruvate ratio as a surrogate for the NAD+/NADH ratio114. The PPP also 
produces NADPH, required by glutathione reductase to maintain levels of reduced 
glutathione, a key anti-oxidant. Flux through the PPP has been estimated in tumours 
by measuring [U-2H, U-13C]glucose conversion to 6-phosphogluconate, a PPP 
intermediate, and recently the production of H13CO3- was detected in mouse liver 
following injection of δ-[1-13C]gluconolactone146, 147. 
 In addition to being an important enzyme co-factor, ascorbic acid (AA) can also 
be oxidised to dehydroascorbic acid (DHA) to reduce oxidative stress. DHA can then 
be reduced back to AA via glutathione or NADPH-dependent reactions. 
Hyperpolarised [1-13C]dehydroascorbic acid and measurement of its reduction to [1-
13C]ascorbic acid has been used to probe intracellular redox status in a number of 
animal models of cancer 148. 
 
1.6.5. Technical developments 
 The transient nature of hyperpolarisation limits its use to metabolic events 
occurring on a timescale of seconds to minutes. Furthermore, each excitation required 
to produce a spectrum or image results in further depletion of the hyperpolarisation, a 
significant factor in the design of pulse sequences. Recent 3D imaging sequences 
have reported nominal spatial resolutions in lactate and pyruvate images of ≤0.003 
cm3, and temporal resolutions <2 s149, 150.  Initial signal availability has been enhanced 
by new polarisers and improved injection protocols102, 105. Prolongation of the 
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polarisation lifetime has been achieved by removal of the radical151, 152. Provided the 
sample remains at low temperature and in a relatively high magnetic field, T1s of 
greater than 20 h are possible151. This would permit centralised hyperpolarisation of 
substrates followed by transport to multiple locations for clinical use, in a similar 
fashion to 18F PET tracers, dispensing with the requirement for a hyperpolariser in 
close proximity to the MRI scanner.  
 Transferring polarisation from hyperpolarised 13C nuclei to spin-coupled 1H 
nuclei can be used to further enhance signal detection. Dynamic 1H imaging of lactate 
methyl protons following injection of [1-13C]pyruvate was recently demonstrated in 
vivo153. The resulting signal enhancements are likely to be greater at the lower 
magnetic field strengths used in the clinic. 
 
1.6.6. Imaging treatment response using hyperpolarised 13C-labelled substrates 
 Using hyperpolarised 13C-labelled substrates to detect treatment response has 
several potential benefits over anatomical imaging and PET methods. First, the ability 
to estimate the rate of a metabolic reaction rather than simply measuring tracer 
accumulation may improve sensitivity and specificity to early post-therapy changes. 
Second, several hyperpolarised substrates can be used simultaneously or 
sequentially allowing multiple metabolic processes to be followed124. This is only 
possible with PET using radionuclides with different half-lives and requires dynamic 
imaging or multiple static acquisitions. Finally, for patient studies it is desirable to avoid 
repeated exposure to ionising radiation. Despite the complete lack of evidence of 
health effects, decades of radiation policy to the contrary has left many clinicians and 
patients irreparably distrustful of repeated medical radiation exposure154, 155.  
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 So far hyperpolarised [1-13C]pyruvate has been the most thoroughly 
investigated hyperpolarised substrate for treatment response monitoring. In animal 
models chemotherapy and radiotherapy have been observed to alter hyperpolarised 
[1-13C]pyruvate metabolism, usually leading to a decrease in lactate production (Table 
1.3). Several methods have been used to quantify the exchange of labelled pyruvate 
and lactate, most frequently measuring the apparent forward reaction rate constant, 
kpl107. The [1-13C]lactate/[1-13C]pyruvate area-under-the-curve ratio, which avoids 
compartmental modelling, has also been widely used and shown to correlate with kpl156. 
 A range of mechanisms, often co-existing, have been proposed to explain the 
decrease in pyruvate to lactate exchange. These include decreased LDH expression 
157-160, apoptosis-induced PARP activation with subsequent depletion of the NADH 
pool 107, 112, 161 and decreased cellularity and size of the exchangeable lactate pool 107, 
159, decreased expression of MCTs 159, 160, 162, 163 and decreased pyruvate kinase M2 
(PKM2) expression (which leads to a decrease in size of the lactate pool)158, 164.  
 Detection of treatment response has been reported in a total of four prostate 
cancer patients undergoing androgen deprivation therapy110, 165. After six weeks of 
therapy there were only small anatomical changes visible on 1H MRI but 
hyperpolarised [1-13C]lactate was virtually undetectable in responding patients. 
Perhaps more significantly, the production of [1-13C]lactate continued to increase in a 
non-responding patient165. Whilst these are useful proof-of-principle examples, it 
should be noted that there is little scope for improving treatment response monitoring 
in prostate cancer where a combination of PSA and multiparametric 1H MRI is already 
effective surveillance166. Indeed, in these four patients, changes in hyperpolarised [1-
13C]pyruvate metabolism correlated with changes in PSA level110, 165. 
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Tumour model Therapeutic Metric Reference 
EL4 murine lymphoma Etoposide Apparent kpl 69, 107 
EL4 murine lymphoma Combretastatin-A4-phosphate  Apparent kpl 
167 
LoVo and HT-29 
colorectal 
adenocarcinoma 
Bevacizumab Apparent kpl 168 
MDA-MB-231 triple-
negative breast cancer Doxorubicin Apparent kpl 
161 
C6-glioma Whole brain irradiation (15 Gy) Apparent kpl 169 
GS-2 glioblastoma Everolimus [1-13C]lactate/pyruvate ratio 170 
C6-glioma B20.4.1.1 (anti-VEGF mAb) [1-13C]lactate/bicarbonate ratio 171 
C3H mouse mammary 
tumor Combretastatin-A4-phosphate [1-
13C]lactate/bicarbonate ratio 172 








Irradiation (10 Gy, and 10 Gy 
x 3) [1-
13C]lactate:pyruvate ratio 159 
SCCVII, MiaPaCa-2 




and [1-13C]lactate/total 13C 
174 
U-HTH83 anaplastic 
thyroid carcinoma Irradiation (5 Gy) Apparent kpl 
175 
C6-glioma Dichloroacetate [1-13C]lactate/bicarbonate ratio 176 
MDA-MB-231 Irradiation (16 Gy) [1-13C]lactate/pyruvate ratio 177 
McA-RH7777 
hepatocellular carcinoma Transarterial embolisation Apparent kpl 
178 
Table 1.3. In vivo pre-clinical studies demonstrating treatment response with 
hyperpolarised [1-13C]pyruvate. 
 
 However, a number of studies have failed to detect treatment response with [1-
13C]pyruvate or shown that it is less sensitive than tumour size measurements173, 178, 
179. In these instances sensitivity may be improved by use of a different substrate. In 
areas of necrosis a decrease in cell membrane integrity results in an increase in 
membrane permeability to fumarate and leakage of fumarase into the extracellular 
space. An increased rate of malate production catalysed by the hydration of fumarate 
by fumarase has been seen in areas of necrosis following injection of hyperpolarised 
[1,4 13C2]fumarate112, 178. High levels of tumour necrosis have been associated with 
resistance to some chemotherapeutics and therefore hyperpolarised [1,4 
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13C2]fumarate may be useful to guide therapy180. For monitoring response to treatment 
it has the significant advantage of being a positive contrast agent.   
 
1.7.  HyperPET: combined hyperpolarised 13C MRI and PET 
 PET-MRI combines improved soft tissue contrast with the functional information 
provided by both PET and MRI and is likely to be of particular use in instances where 
MRI is already the anatomical imaging technique of choice, for example in brain, liver 
and prostate 181. The high sensitivity of [18F]FDG, which permits whole body imaging, 
could be combined with targeted tumour imaging using [1-13C]pyruvate for improved 
metabolic phenotyping. The feasibility of imaging with [18F]FDG and hyperpolarised 
[1-13C]pyruvate in a single session has been demonstrated in pre-clinical studies, 
largely in dogs103, 182-184. In a single animal the improved specificity of [1-13C]pyruvate 
for the Warburg effect permitted differentiation of tumour from glycolytic muscle, which 
was not possible with [18F]FDG182. Albeit with small cohorts, comparison of different 
tumour types (sarcomas and carcinomas) suggests that [18F]FDG uptake and [1-
13C]pyruvate metabolism may provide different metabolic information, and the 
relationship between the two may be specific to tumour type184.  
 [68Ga]-labelled prostate specific membrane antigen ([68Ga]PSMA) is an 
emerging PET technique with improved sensitivity for primary tumours and 
metastases over anatomical imaging and other PET tracers e.g. 
[18F]fluoromethylcholine185, 186. In three patients with prostate cancer combined 
imaging using [68Ga]PSMA and hyperpolarised [1-13C]pyruvate provided 
complementary information. [68Ga]PSMA successfully identified primary and 
metastatic lesions whilst the rate of pyruvate to lactate exchange correlated with 
Gleason scoring and response to anti-androgen therapy165. 
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1.8. Project aims 
 The primary aim of this project was to compare [18F]FDG-PET with 
hyperpolarised [1-13C]pyruvate for the early detection of response to treatment. 
Measurement of hyperpolarised [1-13C]pyruvate metabolism has several theoretical 
advantages over [18F]FDG-PET for detecting early tumour response to treatment. First, 
measurement of [1-13C]pyruvate reduction to lactate has greater tumour specificity 
than [18F]FDG uptake. [18F]FDG uptake in normal tissue could therefore mask tumour 
response particularly if there is a treatment-induced inflammatory reaction. Second, 
by only measuring uptake and phosphorylation [18F]FDG may initially be insensitive to 
any changes that occur in subsequent steps of glycolysis. Conversely, any decrease 
in activity of a glycolytic enzyme is likely to rapidly result in reduced lactate 
concentration detectable using [1-13C]pyruvate. Third, measurement of kinetic 
reaction rates may be more sensitive to early changes in metabolism than 
measurement of [18F]FDG accumulation. Hyperpolarised MRI is able to readily 
estimate kinetic reaction rates whereas calculation of the rate of uptake and inference 
of glucose consumption rates using [18F]FDG-PET requires prolonged dynamic 
acquisitions not suitable for routine clinical use. However, evidence on whether 
hyperpolarised [1-13C]pyruvate can improve on [18F]FDG-PET for detection of 
response to treatment is currently lacking. To date, there have been two preclinical 
studies with differing conclusions. Ravoori et al. reported that in SKOV3 ovarian 
tumours two days of treatment with a tyrosine kinase inhibitor, pazopanib, resulted in 
significant increases in [1-13C]lactate/([1-13C]pyruvate + [1-13C]lactate) ratio but no 
change in [18F]FDG % injected dose per gram. At two weeks this difference was no 
longer observed and at both times differences in tumour volume between control and 
pazopanib-treated mice were more convincing than any metabolic change173.  
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 Witney et al. observed similar reductions in kpl, the rate constant for 
hyperpolarised [1-13C]pyruvate reduction to [1-13C]lactate, and uptake of 2-fluoro-2-
deoxy-D-[U-14C]glucose ([14C]FDG) in EL4 tumours 24 h after treatment with 
etoposide69. This project would improve on the work by Witney et al. by:  
i. Using in vivo [18F]FDG-PET, as per clinical imaging, rather than ex vivo 
scintillation counting of [14C]FDG. 
ii. Comparison of hyperpolarised [1-13C]pyruvate and [18F]FDG for the detection 
of treatment response using the same cohort of animals for both imaging 
modalities.  
iii. Using spectral-spatial pulse sequences capable of imaging hyperpolarised [1-
13C]pyruvate and [1-13C]lactate with 3D spatial resolutions up to 1.25 × 1.25 × 
2.5 mm and a temporal resolution of 2 s149. This permits spatial comparisons of 
[18F]FDG uptake and [1-13C]lactate production.  
 In this thesis four different tumour models are used to compare the ability of 
[18F]FDG-PET and MRI with hyperpolarised [1-13C]pyruvate to detect responses within 
24 h of treatment with the following agents:  
i. EL4, a murine T-cell lymphoma cell line, treated with 67 mg/kg etoposide. 
ii. Eµ-Myc, an autochthonous murine model mimicking human Burkitt’s lymphoma, 
treated with 200 mg/kg cyclophosphamide.  
iii. Colo205, a metastatic human colorectal adenocarcinoma cell line engineered 
to express luciferase and mStrawberry reporter genes, treated with 0.4 mg/kg 
MEDI3039, an experimental TNF-related apoptosis-inducing ligand (TRAIL) 
agonist.  
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iv. MDA-MB-231, a triple negative human breast adenocarcinoma cell line 
engineered to express luciferase and mStrawberry reporter genes, also treated 
with 0.4mg/kg MEDI3039.  
 
 Additionally, a chapter of this thesis is devoted to a study aiming to develop a 
standardised protocol for [18F]FDG-PET acquisition in mice. By performing 3 – 4 hr 
dynamic [18F]FDG-PET scans in different tumour models, the aim was to improve on 
previous work, notably by Fueger et al., to optimise animal handling and timing of static 
[18F]FDG-PET acquisitions187. The models used for this work were:  
i. EL4, murine T-cell lymphoma.  
ii. Eµ-Myc, pre-B cell autochthonous lymphoma.  






 Methods described here are common to two or more chapters. Methods 
unique to a chapter are described within that chapter.  
 
2.1. Animal licence statement 
Animal experiments were performed in compliance with a project licence issued 
under the Animals (Scientific Procedures) Act of 1986. Protocols were approved by 
the Cancer Research UK, Cambridge Institute Animal Welfare and Ethical Review 
Body.  
 
2.2. EL4 cell culture, tumour growth and treatment 
EL4 TIB-39 murine T-cell lymphoma cells (ATCC, Manassas, VA, USA) were 
cultured in RPMI 1640 medium (Gibco, Waltham, MA, USA) supplemented with 10% 
foetal bovine serum and 2 mM L-glutamine. Cell number and viability were monitored 
using Vi-Cell® automated trypan blue staining (Beckman Coulter, Brea, CA, USA). 5 × 
106 EL-4 cells suspended in 200 μL phosphate-buffered saline (PBS) were injected 
subcutaneously into the flanks of female C57BL/6J mice (Charles River, Wilmington, 
MA, USA). Tumours were imaged when they were ~ 1.5 cm in diameter (typically after 
8 – 10 days). Mice were treated with 67 mg/kg etoposide administered intraperitoneally. 
 
2.3. Colo205 cell culture, tumour growth and treatment 
Colo205 metastatic colon adenocarcinoma cells (ATCC) were transduced with 
a lentiviral vector in which mStrawberry red fluorescent protein and luciferase 
expression were under the control of the EF1 promoter188. Cells were cultured in RPMI 
medium (Gibco) supplemented with 2 mM L-glutamine and 10% heat-inactivated 
foetal bovine serum (FBS, Gibco). 5 × 106 cells were resuspended in 0.2 mL PBS. The 
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cell suspensions were implanted subcutaneously into the flanks of female BALB/c 
nude mice (Charles River). Tumours were imaged when they reached ~0.8 cm3, 
typically 6 – 8 weeks after implantation. Mice were treated with 0.4 mg/kg MEDI3039 
administered intravenously.  
 
2.4. MDA-MB-231 cell culture, tumour growth and treatment 
MDA-MB-231 triple-negative breast adenocarcinoma cells (ATCC) were 
transduced with a lentiviral vector in which mStrawberry red fluorescent protein and 
luciferase expression were under the control of the EF1 promoter188. Cells were 
cultured in Dulbecco’s Modified Eagle Medium (Gibco) containing 4 mM L-glutamine, 
25 mM D-glucose and 10% FBS. 5 × 106 cells were resuspended in a 50:50 mix of 
Matrigel (Corning, NY, USA) and complete DMEM. The cell suspensions were 
implanted subcutaneously into the flanks of female BALB/c nude mice (Charles River). 
Tumours were imaged when they reached ~0.8 cm3, typically 6 – 8 weeks after 
implantation. Mice were treated with 0.4 mg/kg MEDI3039 administered intravenously.  
 
2.5. Eμ-Myc transgenic mouse breeding, genotyping and treatment 
Heterozygous Eμ-Myc transgenic mice were bred by the CRUK – CI BRU core 
facility. The presence of the c-Myc transgene and IgH enhancer was confirmed by 
real-time polymerase chain reaction (RT-PCR) for the transgene sequence 
CCAGCCTCAATCTCA189. The forward and reverse primer sequences were 
CCAGATATTGAAGCAGAACGCAAAA and CAAAACGTCGGCTACAGTAACTTT, 
respectively (Transnetyx, Cordova, TN, USA). Adult mice were assessed twice weekly 
for spontaneous development of cervical and axillary tumours189. Mice were treated 
with 200 mg/kg cyclophosphamide. 
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2.6. Anaesthesia of mice 
For all imaging and procedures requiring intravenous cannulation mice were 
anaesthetised by inhalation of 1 – 2.5% isoflurane (Isoflo, Abbotts Laboratories, 
Maidenhead, UK) in a 50:50 mix of air (1 L/min) and oxygen (1 L/min). Temperature 
and respiratory rate were monitored throughout anaesthesia using a rectal 
thermometer and breathing pad (SAII, Stony Brook, NY, USA). 
 
2.7. Hyperpolarisation of [1-13C]pyruvate 
A 44 mg sample of [1-13C]pyruvic acid (Cambridge Isotope Laboratories, 
Tewkesbury, MA, USA) containing 15 mM of OX063 trityl radical (GE Healthcare, 
Amersham, UK) and 1.5 mM of gadoterate meglumine (DOTAREM, Guerbet, Roissy, 
France) was hyperpolarised at ~ 1.2 K by microwave irradiation at 94.110 GHz and 
100 mW in a 3.35 T Hypersense polariser (Oxford Instruments, Abingdon, UK) for 
approximately 1 h. The frozen sample was rapidly dissolved in 6 mL buffer containing 
40 mM HEPES, 94 mM NaOH, 30 mM NaCl and 100 mg/L EDTA heated to 180 ºC 
and pressurised to 10 bar.  
 
2.8. Western blotting 
Freeze-clamped tumour samples were homogenised in 10 µL/mg modified 
RIPA buffer (50 mM HEPES, 1 mM EDTA, 0.7% sodium deoxycholate, 1% Nonidet P-
40, 0.5 M lithium chloride, pH 7.6, 1 cOmplete mini EDTA-free protease inhibitor) using 
a Precellys 24 homogeniser (Precellys, Bertin Instruments, Montigny-le-Bretonneux, 
France). Proteins were separated by SDS-PAGE and transferred to a nitrocellulose 
membrane (iBlot 2, Thermofisher Scientific). Membranes were blocked with 1:1 
Odyssey blocking buffer and Tris-buffered saline (TBS) and incubated with antibody 
 43	
solutions at 4 ºC overnight. Antibodies were detected using multiplexed IRDye 
secondary antibodies and images acquired using an Odyssey CLx (LI-COR 
Biosciences, NE, USA). Quantification was performed using Image Studio 5.2.5 (LI-
COR Biosciences, NE, USA). The antibodies used are listed in Table 2.1.  
Antibody 
Target 
Primary Antibody Manufacturer Secondary Antibody 
and dilution 
LDH-A Rabbit polyclonal IgG Santa-Cruz (sc-33781) Donkey anti-rabbit 1:15000 
MCT1 Rabbit polyclonal IgG Atlas (HPA003324) Donkey anti-rabbit 1:15000 
MCT4 Rabbit polyclonal IgG Santa-Cruz (sc50329) Donkey anti-rabbit 1:15000 
HK2 Rabbit mAb Cell Signalling (C64G5) Donkey anti-rabbit 1:15000 
GLUT1 Goat polyclonal IgG Santa-Cruz (sc-1603) Donkey anti-goat 1:5000 
GLUT3 Goat polyclonal IgG Santa-Cruz (sc-7582) Donkey anti-goat 1:5000 
PARP Rabbit polyclonal IgG Abcam (ab-6079) Donkey anti-rabbit 1:15000 
β-actin Mouse mAb Abcam (ab-6276) Donkey anti-mouse 1:20000 
β-tubulin Mouse mAb Cell Signalling (D3U1W) Donkey anti-mouse 1:20000 
GAPDH Mouse mAb Abcam (ab9484) Donkey anti-mouse 1:20000 
Table 2.1. Antibodies used for western blotting.  
 
2.9. Lactate dehydrogenase (LDH) activity assay 
 Extracts in RIPA buffer were prepared from freeze-clamped tumours as above. 
Samples were diluted so as to achieve a linear reduction in absorbance at 340 nm 
(A340) over 10 min. 1 μL of sample was added to 167.2 μL Tris-NaCl buffer containing 
80 mM Tris, 200 mM NaCl and 0.4 mM NADH. The reaction was started by the addition 
of 31.8 μL 1.6 mM pyruvate. The change in NADH concentration was monitored by 
∆A340 using a PHERAstar FS microplate reader (BMG Labtech, Aylesbury, UK). LDH 




where ∆C is the change in concentration of NAD(H) (mol-1 L-1 min-1), ε is the molar 
extinction coefficient for NADH at 340 nm (6220 M-1cm-1) and l is the path length 
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(0.6061 cm). One unit of LDH activity was defined as the amount of enzyme that 
catalyses the oxidation of 1 µmol NADH min-1 at pH 7.2 and 23 ºC (room temperature).  
 
2.10. Immunohistochemistry (IHC) 
 Tumours were excised immediately post-mortem, immersed in neutral buffered 
formalin and after 24 h transferred to 70% ethanol. Immunohistochemistry was 
performed by Jodi Miller and the Histopathology Core Facility, CRUK Cambridge 
Institute. Tumour sections, 6 µm thick, were de-waxed and rehydrated using a Leica 
ST5020 Multistainer (Leica, Wetzler, Germany) and stained for cleaved caspase-3 
(CC3) and terminal deoxynucleotidyl transferase nick-end labelling (TUNEL). CC3 
staining was performed using a Bond Polymer Refine Detection Kit (DS9800, Leica, 
Wetzlar, Germany) and a 1:200 dilution of CC3 rabbit monoclonal antibody (9664, Cell 
Signalling Technology, Danvers, MA, USA). TUNEL staining was performed using a 
combination of a Bond Polymer Refine Detection Kit (DS9800, Leica, Wetzlar, 
Germany) and a DeadEnd Colorimetric TUNEL System (G7130, Promega, Madison, 
WI, USA). Analysis was performed using Aperio ImageScope 12.3.3 (Leica, Wetzlar, 
Germany). TUNEL % positivity was calculated using an automated positive pixel count 
and subtracting the % positivity of the negative control slide from the positive stained 
slide. CC3 % positivity was calculated using an automated positive pixel count.  
 
2.11. Statistical analysis 
Graphical and statistical analyses were performed using Prism v 6.0 (GraphPad 
Software, La Jolla, CA, USA). Statistical tests performed were paired or unpaired two-
tailed t-tests with errors representing standard deviation, unless stated otherwise. P 
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values are summarised in figures as: <0.0001, ****; 0.0001 – 0.001, ***; 0.001 – 0.01, 





























PET imaging with [18F]FDG is used in pre-clinical studies as a surrogate for 
glucose uptake in normal tissues and tumours. Widespread clinical use of [18F]FDG-
PET, particularly in oncology, has resulted in its use as a gold standard for determining 
the performance of many new imaging agents182, 190. [18F]FDG-PET is affected by 
numerous factors that can be attributed to variations in animal biology, scanner and 
hardware performance, acquisition and reconstruction settings and methods of image 
analysis. Failure to adequately control the external variables results in poor 
reproducibility, a lack of comparability between studies and potentially erroneous 
conclusions. This chapter will focus on the importance of controlling biological factors 
and the timing of static PET acquisitions. 
In clinical practice guidelines such as those produced by the European 
Association of Nuclear Medicine (EANM) and the Quantitative FDG-PET Biomarker 
Committee outline how many factors should be controlled during PET imaging191, 192. 
Prior to clinical [18F]FDG studies, patients are kept in a warm, non-stimulating 
environment and asked to avoid physical activity to minimise background uptake by 
normal muscle and brain tissue. Patients also undergo a period of fasting prior to 
imaging. The aim of this is two-fold: i) to reduce competition from high levels of 
circulating glucose and ii) to maintain steady levels of insulin, variation of which may 
change the distribution of [18F]FDG uptake. The presence of fasting hyperglycaemia 
(>7 mmol/L) can delay imaging as it is considered to alter [18F]FDG distribution and 
reduce the quality of [18F]FDG-PET images although the evidence is not conclusive193-
196. The uptake and slow accumulation of [18F]FDG in tissues is a dynamic process, 
but most clinical PET studies are static acquisitions. The timing of the acquisition is 
therefore of vital importance and the majority of scans are acquired at 60 min after 
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intravenous injection of [18F]FDG, with a tolerance of 55 – 75 min191, 192. This time point 
is a compromise between best contrast and speed as almost all imaging studies 
suggest that the tumour-to-blood ratio (TBR) continues to increase with acquisition 
time197-203. 
Although clinical guidelines do not necessarily optimise [18F]FDG-PET, they 
permit repeat studies acquired on the same scanner (or on cross-calibrated scanners) 
to be adequately compared for answering most clinical questions, which are often 
simple and do not require absolute quantification204.  
In pre-clinical imaging no such guidelines exist and, particularly when being 
used for benchmarking of novel imaging tests, there is a requirement to optimise 
[18F]FDG-PET to avoid potential bias. The work of Fueger et al. is commonly cited and 
has led to the partial standardisation of animal handling187. However, Fueger et al. 
mainly investigated the effects of altered animal handling on [18F]FDG biodistribution 
in normal, non-anaesthetised mice and their investigation of tumours was limited to 
two conditions (fasted and warmed vs. not fasted and not warmed)187. Similarly to 
clinical studies, the timing of static preclinical [18F]FDG-PET acquisitions is typically 
60 min post-injection. The rationale for this time point in rodent studies appears to be 
convenience rather than optimisation, as most studies indicate that TBR continues to 
increase with time187, 205-207. [18F]FDG kinetics may also be different in subcutaneous 
xenograft, orthotopic xenograft and autochthonous tumours205.  
Focussing on tumour imaging, the first aim of this study was to investigate the 
separate effects of pre-warming and fasting on [18F]FDG biodistribution in mice. 
Dynamic 4 h [18F]FDG-PET scans of EL4 murine T-cell lymphoma tumour-bearing 
mice demonstrated that fasting increased tumour uptake and decreased myocardial 
uptake of [18F]FDG, whilst there was no significant effect of pre-warming.  
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 To define an optimal time point for static PET acquisition, dynamic scans of 
mice bearing subcutaneous EL4 T-cell lymphomas and Colo205 human colon 
adenocarcinomas demonstrated that subcutaneous tumour SUVmean and TBR 
continued to increase up to 170 min post-injection with more pronounced increases in 
uptake over time in fasted mice. In Eµ-Myc autochthonous lymphomas there was no 
significant increase in uptake after 30 min post-injection. These results suggest that 
static PET scans 60 min after injection significantly underestimate maximal SUV in 
subcutaneous tumours and later timepoints would increase tumour contrast.  
 
3.2. Methods 
The following methods described in “Chapter 2 - Methods” are used in this chapter: 
2.1. Animal licence statement 
2.2.  EL4 cell culture, tumour growth and treatment 
2.3.  Colo205 cell culture, tumour growth and treatment 
2.5.  Eμ-Myc transgenic mouse breeding, genotyping and treatment 
2.6.  Anaesthesia of mice 
2.11.  Statistical analysis 
 
3.2.1. Animal preparation 
 The effects of animal handling on [18F]FDG-PET of EL4 tumour-bearing mice 
was studied by varying conditions according to Table 3.1. For fasting, mice were 
transferred to a new cage without food for 6 – 10 h. Mice in the fed group were 
transferred to a new cage 6 – 10 h prior to imaging with food freely available. All mice 
had water freely available at all times. For pre-warming mice were placed in a chamber 
heated to 31 ºC, the thermoneutral temperature of mice, for approximately 60 min prior 
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to anaesthesia208. Mice not warmed remained at 18 – 21 ºC, the ambient temperature 
of the animal house, up to induction of anaesthesia. Henceforth pre-warmed mice are 
referred to as “warmed” mice and mice not pre-warmed are referred to as “cold” mice.  
 
Number of mice Conditions 
3 Fasting, pre-warmed 31 ºC 
5 Fasting, no warming 
5 Fed, pre-warmed 31 ºC 
3 Fed, no warming 
Table 3.1. Animal handling conditions for EL4 tumour-bearing mice. 
  
Mice were anaesthetised with isoflurane as described in Methods 2.6. After 
induction of anaesthesia all mice were kept on a heating pad for intravenous tail vein 
cannulation prior to being transferred to the heated bed on a nanoScan PET/CT 
(Mediso, Budapest, Hungary).  Throughout imaging, the temperature and respiratory 
rate of mice were measured using a rectal temperature probe and breathing pad, 
respectively (SAII, Stony Brook, NY, USA). Heating was adjusted to maintain rectal 
temperature between 36 and 37.5 ºC whilst anaesthesia was titrated to maintain a 
respiratory rate of 80 – 120 breaths per min. Venous glucose concentration was 
measured using a StatStrip Xpress glucose meter (Nova Biomedical, Waltham, MA, 
USA) prior to imaging.  
 Colo205 mice (n = 8) were imaged following a period of fasting and pre-
warming as described above. Eμ-Myc mice (n = 4) were pre-warmed but were not 




3.2.2. [18F]FDG-PET imaging 
3 h (Colo205 and Eμ-Myc) and 4 h (EL4) PET acquisitions were started just 
prior to intravenous injection over 30 s of [18F]FDG into each tumour-bearing mouse. 
Data were acquired in list-mode format. A CT image was acquired for anatomic co-
registration and attenuation correction. Scans were reconstructed with an isotropic 
voxel size of 0.6 mm using a three-dimensional ordered-subset expectation 
maximization method, two iterations and six subsets. Images were normalised and 
corrected for decay, dead-time, random events and attenuation. 3 h scans were 
reconstructed into 91 time frames (5 s × 24, 0 – 2 min; 15 s × 12, 2 – 5 min; 30 s × 10, 
5 – 10 min; 1 min × 10, 10 – 20 min; 2 min × 20; 20 – 60 min; 5 min × 6, 60 – 90 min 
and 10 min × 9, 90 – 180 min). 4 h scans were reconstructed into 97 time frames of 
the above durations with an additional six × 10 min segments from 180 – 240 min.  
 
3.2.3. Image analysis 
The images were analysed using Vivoquant 3.0 software (InviCRO, 
Massachusetts, USA). An image-derived arterial input function (AIF) was acquired 
from a 3D ROI drawn manually over the inferior vena cava. To minimize spill-in effects 
the ROI was drawn between the level of the kidneys and diaphragm, where 
contributions from other organs are relatively low, and thresholded at 75% of the 
maximum in the 5 s time frames. A 3D ROI drawn manually over the tumour was Otsu 
thresholded on the last time frame to delineate the tumour. A 3D ROI drawn manually 
over the heart was thresholded above 75% of the maximum to try to define the 






where cimg is the activity concentration (MBq/mL) derived from the image ROI, ID is 
the injected dose (MBq) and BW is the body weight (g) of the animal. 
Patlak graphical analysis was used to estimate the net rate of [18F]FDG uptake 
(Ki) from the linear portion of the graph between 20 and 60 min209. Patlak multiple-time 
graphical analysis assumes irreversible uptake of a tracer into a tissue compartment. 
The rate of accumulation of tracer in a tissue ROI (R) at a time (t) after tracer injection 
can be expressed as: 




where  Cp is the plasma activity, V0 is the blood and interstitial volume (the 
reversible compartment) of the ROI and Cp is the plasma input function. This can be 








 + V0 
When plotted graphically, the slope becomes linear after the free [18F]FDG in 
the reversible compartments has equilibrated with the [18F]FDG in plasma and has a 
gradient equal to Ki. 
 
3.3. Results 
 Twenty-eight mice were injected with 12.75 ± 4.2 MBq [18F]FDG and completed 
dynamic 3 – 4 h PET imaging. Sixteen mice had subcutaneous EL4 tumours, eight 
had subcutaneous Colo205 tumours and four were Eμ-Myc mice.  
 
3.3.1. Fasting reduces blood glucose in EL4 tumour-bearing mice 
Blood glucose was measured in tail vein samples prior to intravenous 
cannulation. Blood glucose was 8.3 ± 1.8 mmol/L (n = 8) in animals allowed access to 
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food up until anaesthesia and 5.2 ± 1.4 mmol/L (P = 0.0029, n = 8) in fasted animals 
(Figure 3.1). Pre-warming animals did not have a significant effect on venous glucose 
concentration.  
 
Figure 3.1. Blood glucose measurements in fed vs. fasted mice.  
 
3.3.2. [18F]FDG biodistribution in EL4 tumour-bearing mice 
EL4 tumour-bearing mice were injected with [18F]FDG intravenously and 
underwent 4 h dynamic PET scans. The exact timing of injection varied slightly and 
the peak activity seen in the inferior vena cava ROI occurred between 10 and 30 s 
after the start of the scan. The tissues irreversibly accumulating the most [18F]FDG 
were the myocardium, tumours and, to a lesser extent, Harderian glands (Figures 3.2 
– 3.6). Initially, perfusion of the liver resulted in a liver SUVmean peak of 2.57 ± 0.5 at 
the 40 s time frame but this decreased from to 0.12 ± 0.1 by the 230 – 240 min time 
frame, indicating very little irreversible uptake. Similarly, there was rapid renal 
perfusion and excretion of [18F]FDG but SUVmean decreased from 6.64 ± 0.6 after 1 – 
1.5 min to a minimum SUVmean in the final time frame of 0.46 ± 0.1, again indicating 
minimal tracer uptake. The SUVmean of the brain cortex peaked at 2.53 ± 0.2 between 
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12 and 24 min and then decreased over the duration of the scan, reaching a minimum 
of 0.85 ± 0.06 in the last time frame. This decrease may be partially due to a large 
vascular component in the brain ROI but the slower rate of decrease compared to the 
liver and blood pools suggests that this decrease is due to slow de-phosphorylation of 
[18F]FDG-6P and partially reversible trapping.  
 
3.3.3. Effect of animal handling on myocardial and tumour [18F]FDG uptake 
The SUVmean values in the 230 – 240 min time frame were used to compare 
final uptake between EL4 tumour-bearing mice under different conditions. Pre-
warming had no significant effect on tumour or myocardial [18F]FDG uptake. However, 
fasting resulted in suppression of myocardial uptake and an increase in tumour uptake 
(Figure 3.3 – 3.8). In cold and fed animals myocardial SUVmean was 13.5 ± 2.9 (n = 3) 
but in cold and fasted animals was 4.90 ± 1.67 (n = 5, P = 0.0015). The pattern was 
similar in warmed mice where myocardial SUVmean was 9.88 ± 3.6 (n = 5) in fed mice 
and reduced to 5.28 ± 0.3 (n = 3) in fasted mice, although due to one outlier in the fed 
group this was not quite significant (P = 0.075) (Figure 3.7 and 3.8). Tumour SUVmean 
was 4.09 ± 0.39 (n = 3) in cold and fed mice and 5.13 ± 0.4 (n = 5; P = 0.01) in fasted 
mice. Similarly in pre-warmed mice tumour SUVmean was 3.47 ± 0.7 (n = 5) in fed mice 
and 4.71 ± 0.4 (n = 3, P = 0.034) in fasted mice.  
 55	
 
Figure 3.2. Time courses of dynamic [18F]FDG-PET scans in warmed and fasted 
EL4 tumour-bearing mice (n = 3). (a) SUVmax and (b) SUVmean.  
 56	
 
Figure 3.3. Dynamic [18F]FDG-PET of a fasted and warmed EL4 tumour-bearing 
mouse demonstrating low myocardial uptake and high tumour uptake. (Rows a 
& d) 3D reconstructions of bone CT and [18F]FDG-PET. Solid blue arrow – inferior 
vena cava (10 s); outline white arrow – right kidney (55 s); solid white arrow – heart 
(240 min); solid yellow arrow – tumour (240 min); outline yellow arrow – bladder (240 
min). Axial [18F]FDG-PET/CT slice through (rows b & e) heart and (rows c & f) tumour. 
The PET voxels covering the bladder are saturated in the later time frames to allow 
the other organs to be visualised.  
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Figure 3.4. Dynamic [18F]FDG-PET scans of a fasted and not warmed EL4 
tumour-bearing mouse demonstrating low myocardial uptake and high tumour 
uptake. (Rows a & d) 3D reconstructions of bone CT and [18F]FDG-PET. Solid blue 
arrow – inferior vena cava (10 s); outline white arrow – right kidney (55 s); solid white 
arrow – heart (240 min); solid yellow arrow – tumour (240 min); outline yellow arrow – 
bladder (240 min). Axial [18F]FDG-PET/CT slice through (rows b & e) heart and (rows 
c & f) tumour. The PET voxels covering the bladder are saturated in the later time 
frames to allow the other organs to be visualised.  
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Figure 3.5. Dynamic [18F]FDG-PET of a fed and warmed EL4 tumour-bearing 
mouse demonstrating high myocardial uptake and low tumour uptake. (Rows a 
& d) 3D reconstructions of bone CT and [18F]FDG-PET. Solid blue arrow – inferior 
vena cava (10 s); outline white arrow – right kidney (55 s); solid white arrow – heart 
(240 min); solid yellow arrow – tumour (240 min); outline yellow arrow – bladder (240 
min). Axial [18F]FDG-PET/CT slice through (rows b & e) heart and (rows c & f) tumour. 
The PET voxels covering the bladder are saturated in the later time frames to allow 
the other organs to be visualised.  
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Figure 3.6. Dynamic [18F]FDG-PET of a fed and not warmed EL4 tumour-bearing 
mouse demonstrating high myocardial uptake and low tumour uptake. (Rows a 
& d) 3D reconstructions of bone CT and [18F]FDG-PET. Solid blue arrow – inferior 
vena cava (10 s); outline white arrow – right kidney (2 min); solid white arrow – heart 
(240 min); solid yellow arrow – tumour (240 min); outline yellow arrow – bladder (240 
min). Axial [18F]FDG-PET/CT slice through (rows b & e) heart and (rows c & f) tumour. 
The PET voxels covering the bladder are saturated in the later time frames to allow 
the other organs to be visualised.  
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Figure 3.7. Mean dynamic SUVmean for animals under different handling 
conditions in the (a) myocardium and (b) EL4 tumours. The occasional steps in 
the time-activity curves (TACs) that can be seen, for example in the myocardium for 





Figure 3.8. SUVmean in the last time frame (230 – 240 min) for all animals (a) 
myocardium and (b) EL4 tumours under different animal handling conditions.  
 
3.3.4. Comparison of [18F]FDG uptake in different tumour models and animal 
handling conditions 
 To find an optimal time point for static [18F]FDG-PET in mouse tumours, uptake 
was compared between EL4, Colo205 and Eµ-Myc models (Figure 3.9). Colo205 
tumour-bearing mice were warmed and fasted prior to imaging, as this was presumed 
to be the optimum conditioning, but Eµ-Myc mice were fed throughout due to the high 
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morbidity of the model. Eµ-Myc cervical tumours were used for comparison although 
uptake in cervical, axillary and inguinal tumours was almost identical (Figure 3.10). In 
cold and fasted mice significant increases in EL4 tumour SUVmean were observed up 
to 170 min post-injection (Figure 3.11 c). In warm and fasted mice and cold and fed 
mice, EL4 tumour SUVmean increased significantly from 60 – 90 min (Figure 3.11 a & 
d). Although there were further small increases under these conditions up to 170 min, 
these were not significant. In warm and fed EL4 mice and Colo205 mice there was 
only a significant increase in tumour SUVmean from 30 – 60 min post-injection (Figure 
3.12 b & e). In Eµ-Myc tumours there were no significant changes in SUVmean between 
30 – 170 minutes and the small decrease in SUVmean seen after 60 min was also 
primarily due to a movement artefact.  
 
Figure 3.9. Tumour SUVmean over time for the different tumour models and EL4 
tumours imaged under different animal handling conditions. Error bars are SEM. 
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Figure 3.10. Uptake in an Eµ-Myc at 90 min post-injection of [18F]FDG. Cervical, 
axillary and inguinal tumours are visible on both the maximum intensity projection (MIP) 
(left) and coronal slice (right). High uptake in the spleen is also visible in the MIP.   
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Figure 3.11. Tumour SUVmean at 30, 60, 90, 170 and 230 min for the different 






3.3.5. Tumour-to-blood SUVmean ratios in the different tumour models 
 Tumour-to-blood ratios have been shown to correlate more closely with 
[18F]FDG Ki than to SUV210. Furthermore, tumour-to-blood ratios provide an indication 
of tumour-to-background contrast, irrespective of any background tissue uptake. The 
input function derived from the vena cava was highly reproducible and after the initial 
peak, decreased up to approximately 100 min post-injection (Figure 2.12). Thus, 
tumour-to-blood ratio and tumour SUVmean followed similar trends. 
 
Figure 3.12. Image derived input function from the inferior vena cava (n = 28). 
The inset shows the SUVmean between 0 and 5 min.  
 
Tumour-to-blood [18F]FDG ratios increased up to 170 min post-injection in all 
fasted mice, although in EL4 warm, fasted mice the low numbers meant that the 
increase was statistically significant only between 90 and 170 min (Figure 2.13 and 
2.14). The increases were less apparent in fed mice. In autochthonous Eµ-Myc 
 66	
tumours the insignificant decrease in tumour-to-blood ratio after 60 minutes was 
primarily due to movement artefact in one animal. 
 
Figure 3.13. Tumour-to-blood SUVmean ratios in different tumour models under 










Figure 3.14. Tumour-blood ratios at 30, 60, 90, 170 and 230 min for the different 
models and different animal handling conditions. These are the same data as 






 Patient studies have shown that delaying [18F]FDG-PET acquisition beyond the 
standard 60 min post-injection may be beneficial. In glioma patients scans performed 
up to 8 h post-injection yielded improved contrast between normal brain and tumour 
due to the higher glucose-6-phosphatase activity in normal brain199. In non-small cell 
lung cancer patients dynamic studies and simulation estimated a time to plateau for 
the tumour SUV of between 130 – 500 min198. Similar results in lymphoma, breast and 
bone cancers suggest that improved tumour-to-background ratio and differentiation of 
malignancy from benign lesions can be achieved by imaging ≥ 2 h post-injection200-203.  
 In rodents the effect of PET acquisition timing has only been studied over 
shorter periods, typically ≤60 min187, 205. Rat mesotheliomas could be differentiated 
from inflammatory lesions at 90 min, but not 45 min, post-injection207. Our study 
demonstrates that in autochthonous Eµ-Myc tumours [18F]FDG uptake peaked around 
60 min but in subcutaneous tumours, under most animal handling conditions, it 
continued to accumulate beyond 60 min and up to 170 min post-injection. The slower 
uptake in subcutaneous tumours may indicate their relatively poorer perfusion 
compared to autochthonous tumours. In all tumours, [18F]FDG uptake was irreversible 
up to 4 h. Other than tumours, only the myocardium and Harderian glands exhibited 
significant irreversible [18F]FDG uptake. Brain, liver and kidney SUVmean decreased 
with time. In normal brain this suggests significant glucose-6-phosphatase activity211. 
Liver TACs closely followed those of the inferior vena cava, meaning [18F]FDG 
retention in the liver was minimal, corroborating previous studies212, 213. Although there 
was rapid urinary clearance of [18F]FDG in all mice, there was very little retention 
[18F]FDG in the kidneys. The decreasing activity of normal brain, liver and kidney with 
time has significant implications for tumour imaging, particularly for orthotopic and 
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autochthonous tumours in those organs as an improved tumour-to-background ratio 
could be expected at later time points.  
This study investigated [18F]FDG biodistribution when mice were fasted and 
warmed to thermoneutral temperature for 1 h prior to anaesthesia, aiming to refine 
previous studies187, 214-216. The anaesthetic regimen was the same for all mice and all 
were warmed immediately following anaesthesia to avoid sub-physiological 
temperatures. Fasting resulted in a 25 – 35% increase in [18F]FDG uptake in EL4 
tumours. The increase in tumour uptake in fasted animals has previously been 
attributed to decreased competition with plasma glucose, although in a rodent study 
supraphysiological hyperglycaemia (>50 mmol/L) was required to demonstrate this214. 
In contrast, fasting decreased myocardial uptake by 47 – 64%, presumably reflecting 
the heart’s ability to utilise other metabolic substrates, such as fatty acids and lactate, 
when blood glucose is suppressed217. Further depression of myocardial [18F]FDG 
uptake may be possible by using sevoflurane anaesthesia216. Pre-warming mice for 1 
h prior to anaesthesia had no significant effect on myocardial or tumour [18F]FDG 
uptake. Therefore one might expect any added benefit of 1 h pre-warming to be small. 
However, pre-warming mice did have the subjective benefit of improving the ease of 
tail-vein cannulation.  
 This study was limited by the relatively low numbers of mice in each group. 
Therefore the trends seen for some animal-handling conditions did not reach 
significance. Nevertheless, a high degree of repeatability was observed between 
animals. There was one significant outlier in the EL4 warm, fed group. The myocardial 
and tumour uptake in this animal correlated strongly with the EL4 warm, fasting group, 
fuelling speculation that the mouse may not have been taking advantage of the freely 
available food prior to the scan. Furthermore, in most fasted mice tumour-to-blood 
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ratios continued to rise throughout these scans. Owing to animal licence restrictions it 
was not possible to study mice continuously for ≥4 h.  
In eleven of the twenty-eight scans phantoms containing approximately 1 MBq 
[18F]FDG were included to ensure linearity throughout the 4 h acquisitions. This 
demonstrated that in time frames of ≤1 min in duration activity was under-estimated 
(Figure 3.16). This reflects a limitation of the PET scanner when reconstructing scans 
based on fewer counts. Consequently, the plasma integral was disproportionately 
underestimated and Patlak analysis was not possible. Time frames after 20 min post-
injection were ≥2 min in duration, therefore the SUV and tumour-to-blood ratios 
reported are valid. Data were acquired in list-mode format and could be reconstructed 
in 2 min time frames from the start to permit kinetic analysis.  
 
 
Figure 3.16. Underestimation of [18F]FDG phantom activity (n = 11) in time 
frames of ≤1 min in duration.  
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 Kinetic analysis would have been further aided by blood sampling, but this is 
technically challenging in mice. Previous studies have used a variety of different 
models to derive an input function from the vena cava, liver and left ventricle. Spill-in 
from the myocardium precluded the use of the left ventricle blood-pool and activity in 
the vena cava was found to be reproducible between studies, particularly at later time 
points. It should be noted that the limited PET resolution means that, despite locating 
the ROI in the upper abdomen where there was minimal uptake in nearby tissues, the 
vena cava ROI will also have contributions from other tissues, especially the aorta. 
This will limit absolute quantification of metabolic rates from [18F]FDG uptake. 
However, these effects and the partial volume effect can be assumed to be similar 
between mice, permitting kinetic comparisons within this study.  
 
3.5. Conclusions 
 These data demonstrate that animal handling has a significant effect on tumour 
[18F]FDG-PET imaging, corroborating the findings of previous studies and permitting 
further refinement of a pre-clinical imaging protocol. Mice should be fasted prior to 
imaging, warmed when anaesthetised and, as per Fueger et al., should remain 
anaesthetised throughout the uptake and imaging period187. This suppresses 
background muscle and heart uptake and also increases tumour [18F]FDG uptake. 
Warming prior to anaesthesia does not have a significant effect on imaging but should 
be considered to improve ease of cannulation.  
 For many purposes static imaging at 60 min post-injection is adequate. In this 
study uptake in autochthonous tumours had plateaued by this time but this was not 
the case for subcutaneous tumours. If optimal imaging is desired, studies performed 
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at later time-points will maximise tumour [18F]FDG uptake and tumour-to-background 
ratios, particularly for mice in the fasted state.
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4. Imaging treatment response with 
hyperpolarised [1-13C]pyruvate and [18F]FDG in 









































 This is the first of three chapters investigating detection of treatment response 
in tumours using combined hyperpolarised [1-13C]pyruvate and [18F]FDG-PET imaging 
(hyper-PET). It describes imaging subcutaneous EL4 murine T-cell lymphomas before 
and 24 h after treatment with etoposide, a topoisomerase II inhibitor. Topoisomerase 
II relieves DNA supercoiling by causing transient double strand breaks, passing an 
intact helix through the gap and then re-ligating the helix. Etoposide inhibits the re-
ligation step, the result being an accumulation of topoisomerase II-induced double 
stranded DNA breaks, activating apoptosis218, 219. Additionally, etoposide induces 
mitochondrial ROS accumulation which inhibits oxidative phosphorylation in a 
complex-I dependent manner and enhances activation of apoptosis220. 24 h after 
etoposide treatment EL4 tumours have previously been shown to decrease in size and 
there is decreased lactate/pyruvate exchange and [14C]FDG uptake69, 107. This chapter 
builds on this previous work by comparing hyperpolarised [1-13C]pyruvate and 
[18F]FDG in the same cohort of animals and using [18F]FDG-PET imaging instead of 
ex vivo scintillation counting of [14C]FDG. 
Fourteen EL4 tumour-bearing mice completed hyper-PET imaging before and 
after treatment. There was a decrease in tumour [18F]FDG uptake in all animals after 
treatment. Initially, labelled lactate/pyruvate ratios were calculated from magnetic 
resonance spectroscopy measurements but these were superseded by the 
development of 2D spectral-spatial (SpSp) echo planar imaging (EPI) and 3D SpSp 
dual spin echo (DSE) imaging sequences149, 221. With all three methods tumour [1-
13C]lactate/[1-13C]pyruvate ratio changed variably in response to treatment. These 
results were partially explained from ex vivo tumour protein expression data showing 




expression of MCT1, MCT4 and LDH or tumour lactate concentration. Poly(ADP-
ribose) polymerase (PARP) cleavage, previously correlated with a decrease of NAD(H) 
availability in tumour cells in vitro, was unchanged by treatment in tumours in vivo69. 
Furthermore, before and after treatment there was highly variable terminal 
deoxynucleotidyl transferase nick-end labelling (TUNEL) and cleaved caspase 3 (CC3) 
staining, histological markers of cell death, potentially accounting for the variable 
response to treatment detected using hyperpolarised [1-13C]pyruvate69, 107.  
 
4.2. Methods 
The following methods described in “Chapter 2 - Methods” are used in this chapter: 
2.1. Animal licence statement 
2.2.  EL4 cell culture, tumour growth and treatment 
2.6.  Anaesthesia of mice 
2.7.  Hyperpolarisation of [1-13C]pyruvate 
2.8.  Western blotting 
2.9  Lactate dehydrogenase (LDH) activity assay 
2.10.  Immunohistochemistry (IHC) 
2.11.  Statistical analysis 
 
4.2.1. Animal preparation 
EL4 tumour-bearing mice were fasted for 8 – 12 h prior to anaesthesia and 







4.2.2. Tumour volume estimates 





where x and y are the maximum tumour diameters of two perpendicular planes222.  
 
4.2.3. 13C MR spectroscopy of EL4 tumours 
Experiments were performed in a 7.0 T horizontal bore magnet (Agilent, Palo 
Alto, CA, USA) using an actively decoupled dual-tuned 13C/1H volume transmit coil 
(Rapid Biomedical, Rimpar, Germany) and a 20 mm diameter 13C receiver coil (Rapid 
Biomedical).  For anatomical reference, T2-weighted 1H images were acquired using 
a fast spin-echo (FSE) pulse sequence. Twenty axial images were acquired with a 
slice thickness of 1 mm, repetition time (TR) 2.24 s, echo time (TE) 48 ms, 2 – 4 
averages, data matrix 256 × 256, FOV 40 × 40 mm. Coronal and sagittal 1H images 
had a slice thickness of 2 mm, TR 2.05 s, TE 48 ms, 2 averages, data matrix 512 × 
256, FOV 80 × 40 mm. Injection of [1-13C]pyruvate was delayed until at least 40 
minutes after [18F]FDG injection to minimise the possible effect of pyruvate on 
[18F]FDG uptake. Immediately after injection of 200 μL ~75mM [1-13C]pyruvate, single 
transient spectra were acquired each second for three minutes from a 10 mm thick 
slice through the tumour using a slice-selective excitation pulse with nominal 5° flip 
angle, spectral width of 6010 Hz and 1024 spectral points. Spectra were summed, 
peak-fitted and the labelled lactate/pyruvate area under the curve (AUC) ratios 





4.2.4. 2D echo planar imaging (EPI) of hyperpolarised [1-13C]pyruvate and [1-
13C]lactate  
 A 6 mm axial 1H reference slice was acquired using the FSE sequence as 
above. The 13C imaging sequence acquired a 2D EPI k-space, starting with a spectral-
spatial (SpSp) excitation pulse and slice selection gradient, followed by a train of 20 
bipolar readout gradients and, simultaneously, a train of 19 blipped phase-encoding 
gradients (Figure 4.1). A 6 mm axial slice was selected covering the tumour with a 
FOV 40 × 40 mm. The acquisition matrix was 32 × 32, but only four k-space lines were 
acquired before the centre of k-space in order to minimise the echo time (TE) and 
enhance the SNR. Hence, only 20 bipolar readout gradients were used (acquiring 
62.5% of k-space). The SpSp RF pulse alternately excited the [1-13C]pyruvate and [1-
13C]lactate resonances with a TR of 2 s for each metabolite. The RF pulse had a 
duration of 15.936 ms, 200 Hz passband width, 1412 Hz between replicate bands and 
a targeted a 15° flip angle using a peak RF power of 0.0386 Gauss. The receiver 
bandwidth was set to 125 kHz with an echo spacing of 536 μs and bandwidth per pixel 
in the phase encoding direction of 58.3 Hz. The sequence was started immediately 
following injection of [1-13C]pyruvate221. Images were acquired over 60 s and analysed 
in MATLAB (Mathworks, Natick, MA, USA). A 2D ROI over the tumour was defined 
using the 1H reference scan. Labelled lactate/pyruvate AUC ratios were calculated 





Figure 4.1. EPI sequence for 2D 13C imaging.  
 
4.2.5. 3D dual spin echo (DSE) 13C imaging of [1-13C]pyruvate and [1-13C]lactate 
 13C images were acquired using a SpSp pulse sequence and 3D spiral DSE 
acquisition (Figure 4.2)223. The SpSp excitation pulse alternately excited [1-
13C]pyruvate and [1-13C]lactate resonances (calculated from the measured water 
proton frequency) at a temporal resolution of 2 s per metabolite. The eighth pair of 
acquisitions was used as a reference scan where the z-gradients were turned off 
except for the slice selection gradient and the spoiler. A spherical stack of spirals was 
acquired at two spin echoes after a single excitation pulse. Flip angles were 15º for [1-
13C]pyruvate and 90º for [1-13C]lactate, respectively, FOV was 40 × 40 × 20 mm with 
a nominal spatial resolution was 1.25 × 1.25 × 2.5 mm in the x, y and z planes, 
respectively. In initial experiments the sequence started immediately after rapid 
injection of hyperpolarised [1-13C]pyruvate (15 mL/kg). [1-13C]pyruvate and [1-
13C]lactate images were acquired alternately each second for 90 s and analysed in 
MATLAB (Mathworks, Natick, MA, USA). A 3D region of interest (ROI) over the tumour 
was defined on the T2-weighted image. The [1-13C]lactate/[1-13C]pyruvate signal ratio 





Figure 4.2. (a) 3D 13C imaging pulse sequence and (b) its 3D k-space trajectory.  
 
4.2.6. [18F]FDG-PET imaging 
After MR acquisition the bed with the mouse in situ was transferred to a 
NanoPET/CT (Mediso, Budapest, Hungary) for a 30 min PET acquisition starting at 60 
min post [18F]FDG injection. A helical CT was acquired for anatomical reference and 
attenuation correction (acquisition settings: 65 kVp, 1100 ms exposure, maximum 
FOV, 360 projections). Static PET images, with a nominal isotropic resolution of 0.3 
mm, were reconstructed using a 3D ordered-subset expectation maximization method 
using a one to three coincidence mode, eight iterations and six subsets. Images were 
normalised and corrected for decay, dead time, random events and attenuation.  
Images were analysed using VivoQuant v2.00 software (InviCRO, Boston, MA, USA). 
A 3D region of interest (ROI) was drawn manually over the tumour and Otsu 
thresholding used to delineate the tumour. For semi-quantitative analysis, mean and 





where cimg is the activity (expressed as MBq/mL) derived from the image ROI, ID is the 




4.2.7. Tumour lactate quantification 
 Tumour extracts were deproteinised by the addition of 5 µL/mg tissue 2 M 
perchloric acid (PCA) and homogenisation using a Precellys 24 homogeniser (Stretton 
Scientific, Stretton, UK). Samples were centrifuged at 13,000 g for 2 min and the 
supernatant pH corrected to 7.0 with 2 M KOH. Samples were centrifuged at 13,000 
g for 15 min and the supernatant taken for analysis. Colourimetric quantification of 
lactate was performed using an L-lactate assay kit (ab65331, Abcam, Cambridge, UK) 
and the A450 measured using a PHERAstar FS microplate reader.  
 
4.3. Results 
4.3.1. In vitro response of EL4 cells to etoposide treatment 
The response of EL4 cells to etoposide was confirmed in vitro by the addition 
of 15 µM etoposide to cell suspensions (Figure 4.3). After 8 h the cell proliferation ratio 
(number of viable cells at t = 𝑥 / number of viable cells at t = 0) was 1.5 ± 0.3 (n = 6) 
in untreated flasks and 1.2 ± 0.1 (n = 12, P = 0.004) in those treated with etoposide. 
After 20 h of culture the cell proliferation ratio increased to 3.1 ± 0.7 (n = 6) in untreated 
flasks but dropped to 0.77 ± 0.1 (n = 12) in etoposide-treated flasks, representing a 
significant inhibition of proliferation (P = <0.0001).  
 
4.3.2. In vivo volume response of EL4 tumours to etoposide treatment 
Tumours were grown by subcutaneous implantation of EL4 cells in the flanks 
of mice. Tumours increased in volume up to nine days post-implantation and were 
then treated with a single dose of etoposide i.p. (Figure 4.4). Treatment resulted in a 
decrease in volume of all tumours within 24 h, with a mean decrease of 19.5 ± 11% (n 




and tumours disappeared completed in <18 days. In two mice tumours started to grow 
5 – 6 days after treatment. Treatment also resulted in a decrease in bodyweight in all 
mice from 22.4 ± 1.7 to 20.4 ± 1.0 g (n = 9; P = 0.0003) 24 h after treatment.  
 
Figure 4.3. The change in number of viable EL4 cells in response to 15 µM 
etoposide in vitro. The cell proliferation ratio is the (number of viable cells at t = 𝑥 / 
number of viable cells at t = 0).  
 
Figure 4.4. Response of EL4 tumours etoposide. Mice (n = 8) received a single 
intraperitoneal dose of 67 mg/kg etoposide at day 9 (arrow) post-implantation. The 
solid lines indicate mice that responded completely to etoposide while the dotted lines 




4.3.3. Imaging of early treatment response with hyperpolarised [1-13C]pyruvate 
and [18F]FDG-PET 
MR and [18F]FDG-PET imaging was completed in fourteen EL4 tumour-bearing 
mice. [18F]FDG uptake decreased in all tumours 24 h after etoposide treatment, with 
SUVmax decreasing from 8.8 ± 1.8 pre-treatment to 5.2 ± 0.84 post-treatment (n = 14, 
P = <0.0001) (Figure 4.5).  
 
 
Figure 4.5. EL4 tumour SUVmax before and 24 h after treatment with etoposide.  
 
 MR spectroscopy, 2D SpSp EPI 13C imaging and 3D DSE 13C imaging was 
performed in seven, four and three mice, respectively (Figure 4.6). There was no 
significant change in mean [1-13C]lactate/[1-13C]pyruvate ratio in EL4 tumours which 
were 1.87 ± 1.1 before and 1.73 ± 1.0 after treatment. Despite the lack of reduction in 
labelled lactate/pyruvate ratio after treatment, the imaging methods demonstrated a 





Figure 4.6. EL4 tumour [1-13C]lactate/[1-13C]pyruvate ratio before and 24 h after 
etoposide treatment. (a) Tumour lactate/pyruvate ratios measured using magnetic 
resonance spectroscopy; (b) example summed spectrum before and (c) after 
treatment. The [1-13C]pyruvate and [1-13C]lactate resonances are at 173 p.p.m. and 
185 p.p.m., respectively. (d) Tumour lactate/pyruvate ratios measured using 2D EPI 
13C imaging and example images (e) before and (f) after treatment (g) Tumour 
lactate/pyruvate ratios measured using 3D DSE 13C imaging (note the reduced scale) 
and an example axial slice through the middle of the tumour (h) before and (j) after 




4.3.4. The effect of etoposide treatment on protein expression, LDH activity and 
lactate concentration in EL4 tumours 
Tumour expression of the enzymes and transporters involved in [18F]FDG 
uptake and [1-13C]pyruvate uptake and reduction to [1-13C]lactate were investigated 
by western blotting (Figure 4.8). GLUT1 expression decreased (relative to β-actin) 
from 0.035 ± 0.009 (n = 5) to 0.016 ± 0.006 (n = 9, P = 0.0006) 24 h after etoposide 
treatment. GLUT3 expression also decreased after treatment from 0.020 ± 0.007 (n = 
5) to 0.007 ± 0.005 (n = 9, P = 0.0012). HK2, responsible for phosphorylation and 
subsequent trapping of [18F]FDG, was not affected by etoposide treatment. The 
expression of MCT1 and MCT4, responsible for pyruvate and lactate membrane 
transport, were not significantly altered by treatment although there was a non-
significant increase in MCT1 expression after treatment (P = 0.08). LDH expression, 
activity and the tumour lactate concentration were not affected by treatment (Figure 
4.7 and 4.8). There was also no change in PARP cleavage, previously correlated with 
NAD(H) depletion in vitro69, 107. 
 
Figure 4.7. (a) EL4 tumour lactate concentration and (b) LDH activity before and 





Figure 4.8. Changes in membrane transporter and enzyme expression in EL4 
tumours 24 h after etoposide treatment.  Arrows above the western blots indicate 
post-treatment tumour samples. Expression of: (a) LDH-A; (b) MCT1; (c) MCT4; (d) 
cleaved PARP; (e) HK2; (f) GLUT1; (g) GLUT3 expression and (h) HK2 expression. 




4.3.5. TUNEL and CC3 IHC in EL4 tumours 
Histological markers of cell death did not manifest a significant effect of etoposide 
treatment (Figure 4.9).  
 
Figure 4.9. (a) TUNEL and (b) CC3 immunohistochemistry in untreated and 
etoposide-treated tumours with corresponding sections for each stain 
underneath each graph. Two sections are shown from different tumours excised at 
day five and day ten pre-treatment and day ten post-treatment. All images are 
identically scaled and the scale bars are 5 mm. Abbreviations: PostTx – post-treatment. 
± 1.7% in tumours excised after eight days. By day ten it had increased to 37 ± 7.4% 
in untreated tumours but was only 9.9 ± 7.7% in post-treatment tumours. The 
implication from the histopathology results is that, independent of etoposide treatment, 






Tumours were excised at five, eight, nine and ten days post-implantation in untreated 
mice. Mice were treated on day nine with etoposide and tumours excised 24 h later 
(day ten post-implantation). TUNEL positivity was fairly constant in untreated tumours 
excised between five and ten days and increased non-significantly from 4.75 ± 0.9 % 
in day ten untreated tumours to 11.84 ± 10.2 % in post-treatment tumours. CC3 
staining was highly variable in untreated tumours. At day five CC3 positivity was 61.65 
± 5.0% but was only 2.26  
 
4.4. Discussion 
 This study demonstrates the feasibility of imaging mice using hyperpolarised 
[1-13C]pyruvate MRI/S and [18F]FDG-PET in a single session (<2 h) before and after 
treatment. Furthermore, the use of 13C imaging techniques allowed the spatial 
distributions of [1-13C]pyruvate, [1-13C]lactate and [18F]FDG to be compared. Lacking 
a combined PET/MRI scanner, this was achieved by transferring the mouse bed 
between the MRI and PET/CT, permitting co-registration of MR and PET/CT images. 
The limited resolution of the 13C images, particularly in the z dimension (6 mm for the 
2D EPI sequence and a nominal 2.5 mm for the 3D DSE sequence) is a limiting factor 
when comparing with PET images. Nevertheless, the distribution of [18F]FDG uptake 
and [1-13C]lactate production were similar in 2D and 3D images.  
To compare detection of tumour treatment response between the two metabolic 
imaging techniques the EL4 tumour model was chosen for its rapid growth, sensitivity 
to the topoisomerase II inhibitor etoposide and availability of similar previous studies69, 
107. Treatment resulted in a decrease in tumour size of approximately 20% in 24 h, 
replicating the findings of Day et al.107. Treatment also resulted in a 41% decrease in 




Witney et al.69. In that study the decrease in [14C]FDG uptake was attributed to 
decreased plasma membrane expression of GLUT1 and GLUT3, observed in vitro. In 
contrast, in this study there was decrease in total GLUT1 and GLUT3 expression in 
the tumours in vivo. 
Unexpectedly, this study failed to demonstrate a consistent decrease in 
exchange between labelled pyruvate and lactate, contrary to the findings of Witney et 
al. and Day et al. who reported decreases in flux between pyruvate and lactate of 38 
and 25%, respectively69, 107. Notably, Witney et al. reported a significant reduction in 
[18F]FDG uptake at only 16 h post-treatment, preceding a decrease in pyruvate/lactate 
exchange69. However, ex vivo tumour analysis revealed important differences 
between the EL4 models used in this study and the previous work. Previously cell 
death after etoposide treatment was reported to increase by approximately 32%107. In 
the current study TUNEL staining only increased by approximately 7% and at day 10 
CC3 positivity decreased by approximately 27%. The EL4 cells used in the current 
study were derived from cells obtained from ATCC in 2014 and were not the same as 
those used in previous studies. In studies (including this one) using the new cells we 
have observed highly variable pre-treatment cell death. Furthermore, treatment did 
not result in reductions in LDH activity, lactate concentration, LDH and MCT 
expression, that would limit flux between pyruvate and lactate. Over-activation of 
PARP in response to etoposide-induced DNA damage has previously been correlated 
with NAD(H) depletion and subsequent reduction in pyruvate to lactate flux in vitro69, 
107. PARP inactivation by caspase-3 is a hallmark of apoptosis and has been observed 
on a similar timescale69. Again, this study did not demonstrate any difference in PARP 




 In addition to the biological explanations for the lack of treatment response 
detectable using hyperpolarised [1-13C]pyruvate, there were also technical limitations. 
The fast imaging sequences developed here enabled 3D in vivo spatial comparisons 
between [1-13C]pyruvate, [1-13C]lactate and [18F]FDG. Initially, the SNR and 
reproducibility of the 3D DSE sequence was low. The high flip angles (15º and 90º for 
[1-13C]pyruvate and [1-13C]lactate, respectively) and imaging from the start of injection 
resulted in depletion of the polarisation and available signal in <15 s. Improvements 
were made by three alterations to the sequence and injection protocol. The flip angles 
were reduced to 5º and 45º for [1-13C]pyruvate and [1-13C]lactate, respectively. The 
injection protocol was changed to an infusion over 8 s, instead of a rapid bolus, and 
the imaging sequence was commenced 2 s after the start of injection. Five [1-
13C]pyruvate images were acquired with a 2 s frame rate for the first five seconds 
before the first acquisition of a [1-13C]lactate image. Thereafter [1-13C]pyruvate and [1-
13C]lactate images were acquired alternately each second. These alterations improved 
SNR and preserved signal for >60 s. This improved version of the sequence and 
injection protocol is used in Chapters 5 & 6.  
 
4.5. Conclusions 
 This study demonstrates the feasibility of combined in vivo imaging using 
hyperpolarised [1-13C]pyruvate MRI and [18F]FDG-PET. Here these measurements 
were used to detect response of EL4 tumours to etoposide. 24 h after treatment there 
was a reduction in tumour volume and [18F]FDG uptake. Contrary to previous findings, 
treatment did not consistently decrease flux between [1-13C]pyruvate and [1-




This study indicates that, for some tumours and chemotherapeutic agents, [18F]FDG 
may be a more sensitive marker of response to treatment than [1-13C]pyruvate.    
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5. Imaging treatment response with 







The vast majority of in vivo pre-clinical imaging studies have been performed 
using subcutaneous models. Most models are fast growing and reproducible, allowing 
large numbers of tumours to be grown at relatively low cost. Subcutaneous implants 
permit tumour growth to be monitored non-invasively and, of particular importance for 
MRI studies, tumours can be fixed externally to minimise movement artefacts and 
optimise SNR. However, the artificial site, lack of diversity in the tumour 
microenvironment, poor perfusion, a rodent immune system (which is 
immunocompromised when used for human tumour cell lines) and frequent use of cell 
lines that have been passaged for decades leads to most subcutaneous tumours 
bearing little resemblance to the human disease they model224, 225. Orthotopic models 
offer an improvement by growing at a more natural site but still have the other 
limitations of implanted tumours.  
 Of all the available models genetically engineered mouse (GEM) cancer 
models provide the most complete representation of tumour development, progression, 
stroma, immune system interaction and angiogenesis226. Although the “natural” 
development of autochthonous tumours has significant advantages for modelling 
disease, the models are invariably challenging to work with. Animals have many of the 
associated morbidities associated with cancer, e.g., ascites, neurological deficits and 
respiratory compromise. This is particularly challenging for imaging research as the 
mice often poorly tolerate prolonged anaesthesia. Relatively slow and variable rates 
of tumour development are often combined with a small window of opportunity 
between the appearance of tumours and study-limiting morbidity. Furthermore, the 
greater heterogeneity of tumours that develop is not always an advantage in a pre-




 The Eµ-Myc GEM model was developed in the late 1980s by injection of the 
Eµ-Myc transgene into the pronucleus of fertilized mouse eggs189, 227. The transgene 
consists of a normal Myc gene coupled to the Ig heavy chain (IgH) enhancer mimicking 
the t(8;14) translocation seen in most Burkitt’s lymphomas. The transgene is 
expressed exclusively in B lymphocytes of the mice and results in development of pre-
B and B lymphomas. Typically within six months mice develop lymphomas (inguinal, 
axillary, cervical, para-thymic and para-aortic), thymomas, small bowel and 
intracranial tumours and a subset also have a leukaemia component to their disease189. 
Furthermore, sensitivity of Eµ-Myc tumours to cyclophosphamide, a nitrogen mustard 
that alkylates guanine residues of DNA leading to apoptosis, has been described 
previously228, 229.  
 The aim of this study was to compare hyperpolarised [1-13C]pyruvate and 
[18F]FDG-PET as methods to detect response 24 h after treating Eµ-Myc tumours with 
cyclophosphamide. 13C MRS and CSI with [1-13C]pyruvate were used in an initial 
cohort of six mice as the experiments pre-dated the development of more 
sophisticated sequences. The MRS measurements suggested that treatment resulted 
in a mean decrease of 71% in the apparent kPL in cervical tumours. However, in a 
separate cohort imaged with [18F]FDG-PET, although there was an obvious decrease 
in the size of all tumours, [18F]FDG uptake in the cervical tumours was difficult to 
interpret due to significant uptake in normal surrounding tissues, particularly in muscle 
and the salivary glands. The effect of contributions of surrounding tissues was 
elucidated by autoradiography and co-registered histology. Subsequently, by drawing 
a small ROI over the tumour regions, spill-in was avoided and a 42% decrease in 




 In the initial cohort, mice were awake during the [18F]FDG uptake period due to 
concerns about the animals tolerance of prolonged anaesthesia. In a cohort of mice 
undergoing simultaneous 3D MRI with hyperpolarised [1-13C]pyruvate and [18F]FDG-
PET the uptake in normal tissues was substantially reduced by mice remaining 
anaesthetised throughout the uptake period. Similar decreases in labelled pyruvate to 
lactate exchange, [18F]FDG uptake and tumour volume were observed in this cohort. 
Unfortunately there were significant limitations of the model. Not only was there a high 
mortality rate from imaging but the effect of animal handling and anaesthesia resulted 
in control mice having similar decreases in tumour volume, pyruvate to lactate 
exchange and [18F]FDG uptake to mice treated with cyclophosphamide.  
 
5.2. Methods 
The following methods described in “Chapter 2 - Methods” are used in this chapter: 
2.1. Animal licence statement 
2.5.  Eμ-Myc transgenic mouse breeding, genotyping and treatment 
2.6.  Anaesthesia of mice 
2.7.  Hyperpolarisation of [1-13C]pyruvate 
2.11.  Statistical analysis 
 
5.2.1. Animal preparation 
Mice were kept in a warmed chamber (31 ºC) for 1 h prior to anaesthesia before 







5.2.2. Hyperpolarised [1-13C]pyruvate MRS and chemical shift imaging (CSI) 
NMR / MRI was performed in a 7.0 T horizontal bore magnet (Agilent, Palo Alto, 
CA, USA) using an actively decoupled dual-tuned 13C/1H volume transmit coil (Rapid 
Biomedical, Rimpar, Germany) and a 20 mm diameter 13C receiver coil (Rapid 
Biomedical).  For anatomical reference, T2-weighted 1H images were acquired using 
a fast spin-echo (FSE) pulse sequence. Twenty axial images were acquired with a 
slice thickness of 1 mm, repetition time (TR) 2.245 s, echo time (TE) 48 ms, 2 – 4 
averages, data matrix 256 × 256, FOV 40 × 40 mm. Coronal and sagittal 1H images 
had a slice thickness of 2 mm, TR 2.05 s, TE 48 ms, 2 averages, data matrix 512 × 
256, FOV 80 × 40 mm. Spectroscopic measurements were made using a 10 mm 
oblique slice through the cervical tumour. Immediately after injection of 400 μL 
hyperpolarised [1-13C]pyruvate single transient spectra were acquired each second for 
three minutes from a 10 mm thick slice through the tumour using a slice-selective 
excitation pulse with a nominal 5° flip angle, spectral width of 6010 Hz and 1024 data 
points. 13C spectroscopic data were processed using MATLAB (MathWorks, Natick, 
MA, USA). The integrated peak intensities of hyperpolarised [1-13C]pyruvate and [1-
13C]lactate were fitted to the modified Bloch equations for two-site exchange to obtain 







dt = -R1,L LZ-L∞ +kPLPZ-kLPLZ 
dPZ
dt = -R1,P PZ-P∞ +kLPLZ-kPLPZ 
where L is lactate, P is pyruvate, LZ and PZ are the z-magnetisations of the 13C nucleus 




lattice relaxation rates (1/T1) for lactate and pyruvate, respectively, and L∞ and P∞ are 
their equilibrium magnetisations, which are effectively equivalent to their 
concentrations. The relaxation rates were assumed to be the same for lactate and 
pyruvate.  
 Chemical shift images were acquired from a 6 mm axial slice through the 
tumour between 20 and 50 s after injection of hyperpolarised [1-13C]pyruvate. The 
imaging sequence was the same as that used for the spectroscopic measurements, 
with additional phase-encoding gradients preceding signal acquisition (TR, 30 ms; TE, 
0.85 ms; spectral width, 6010 Hz; spectral points, 128; FOV, 40 × 40 mm; data matrix, 
32 × 32). 13C MRS was performed by Tiago Rodrigues and Mikko Kettunen.  
 
5.2.3. [18F]FDG-PET imaging 
 Mice were anaesthetised and 9.4 ± 1.2 MBq of [18F]FDG injected via tail vein. 
Mice were awakened after injection and kept in the warming box before being re-
anaesthetised prior to a 10 min PET acquisition at 90 min post-injection. Static PET 
images, with a nominal isotropic resolution of 0.3 mm, were reconstructed using a 3D 
ordered-subset expectation maximisation method, a one to three coincidence mode, 
eight iterations and six subsets. Images were normalised and corrected for decay, 
dead time, random events and attenuation.  Images were analysed using VivoQuant 
v2.00 software (InviCRO, Boston, MA, USA). A 3D ROI was manually drawn over the 







5.2.4. Combined [18F]FDG-PET and 3D-DSE 13C imaging of [1-13C]pyruvate and 
[1-13C]lactate 
 Venous glucose concentration was measured using a StatStrip Xpress glucose 
meter (Nova Biomedical, Waltham, MA, USA) prior to imaging. [18F]FDG (12.7 ± 0.8 
MBq) (Alliance Medical, Guildford, UK) was injected intravenously and mice remained 
anaesthetised throughout the uptake period. MRI was performed in a 7.0 T horizontal 
bore magnet (Agilent, Palo Alto, CA) using an actively decoupled dual-tuned 13C / 1H 
volume transmit coil (Rapid Biomedical, Rimpar, Germany) and a 20 mm diameter 13C 
receiver coil (Rapid Biomedical) placed under the cervical tumours. To facilitate co-
registration between PET and MR images, the receiver coil and hindquarters of the 
mice were fixed to the mouse bed using R&S Turboflex (CFPM, Aulnay-sous-Bois, 
France). For anatomical reference, eight axial T2-weighted 1H images were acquired 
using a fast-spin echo sequence with a slice thickness of 2.5 mm, FOV 40 × 40 mm, 
and matrix size of 256 × 256 points. 13C images were generated using a SpSp pulse 
sequence and 3D DSE acquisition (Figure 5.1)149. Flip angles were 7º for [1-
13C]pyruvate and 45º for [1-13C]lactate, respectively, FOV was 40 × 40 × 20 mm with 
a nominal spatial resolution of 1.25 × 1.25 × 2.5 mm in the x, y and z planes, 
respectively. Five [1-13C]pyruvate images were acquired prior to the first [1-13C]lactate 
image after which each metabolite was excited at a temporal resolution of 2 s per 
metabolite (Figure 5.1c). The eighth pair of acquisitions was used as a reference scan 
where the z-gradients were turned off except for the slice selection gradient and the 
spoiler. At 1 h after injection of [18F]FDG hyperpolarised [1-13C]pyruvate (15 mL/kg) 
was infused intravenously over 8 s and the pulse sequence was started 2 s after the 
start of the infusion. Five [1-13C]pyruvate images were acquired prior to the first [1-




(Figure 5.1). Images were acquired over 90 s and analysed in MATLAB (Mathworks, 
MA, USA). A 3D ROI over the tumour was defined on the T2-weighted image. The [1-
13C]lactate/[1-13C]pyruvate signal ratio was calculated from the area under the curve 
of their respective time courses.  
 
Figure 5.1. (a) 3D 13C imaging pulse sequence, (b) its k-space trajectory and (c) 
the experiment timeline. Hyperpolarised [1-13C]pyruvate is injected between 0 – 8 s 
with [1-13C]pyruvate image acquisition every 2 s for the first 8 s followed by alternate 
[1-13C]pyruvate and [1-13C]lactate image acquisitions every second.  
 
After completion of MRI the bed with mouse in situ was transferred to a 
nanoScan PET/CT (Mediso, Budapest, Hungary).  A 15 min static PET acquisition 
began at 90 min post-injection of [18F]DG. Static PET images, with a nominal isotropic 
resolution of 0.3 mm, were reconstructed using a 3D ordered-subset expectation 
maximisation method with a one to three coincidence mode, eight iterations and six 
subsets. Images were normalised and corrected for decay, dead-time, random events 
and attenuation. For anatomical reference and attenuation correction a whole-body 




time and 0.21 mm isotropic voxels.  The images were analysed using Vivoquant 3.0 
software (InviCRO, Massachusetts, USA). A 3D region of interest was drawn manually 
over the subcutaneous tumour and Otsu thresholding applied to delineate the tumour. 
For semi-quantitative analysis, mean and maximum standardised uptake values were 





where cimg is the activity concentration (MBq/mL) derived from the image ROI, ID is 
the injected dose (MBq) and BW is the body weight (g) of the animal.  
 
5.2.5. Whole-body [18F]FDG autoradiography 
Eµ-Myc mice (n = 6 untreated and n = 4 treated) were anaesthetised and 
injected intravenously with [18F]FDG and then awakened. At 80 min post-injection mice 
were re-anaesthetised and sacrificed by intravenous injection of pentobarbital and 
immediately frozen by submersion in a bath of isopentane surrounded by an outer 
liquid nitrogen bath. Ten µm-thick axial cryo-sections (CM3050S Cryostat, Leica) 
taken through the cervical tumour region were thaw-mounted onto microscope slides. 
Slides were placed adjacent to a storage phosphor screen (GE, Chicago, IL, USA) 
overnight and the screen imaged with a pixel size of 10 µm (Typhoon Biomolecular 
Imager, Amersham Biosciences, Little Chalfont, UK). The slides were H&E stained 
and autoradiography and H&E images were co-registered manually. Tissue-to-muscle 









5.3.1. Hyperpolarised [1-13C]pyruvate MRS and [18F]FDG-PET in separate 
cohorts of mice 
 Eµ-Myc mice (n = 6) were imaged before and 24 h after treatment with 
cyclophosphamide (Figure 5.2). There was a decrease in the apparent kPL from 0.12 
± 0.03 to 0.04 ± 0.03 after treatment (P = 0.002). In a separate cohort of Eµ-Myc mice 
(n = 4) [18F]FDG-PET results were difficult to interpret. Tumour volume obviously 
decreased in all mice (n = 4) but, compared to the homogenous uptake in pre-
treatment tumours (Figure 5.3c), post-treatment there were small areas of high uptake 
that could have been tumour tissue or spill-in from adjacent normal tissue (Figure 5.3 
d & e). Whether the ROI included or excluded these areas significantly impacted post-
treatment SUVs (Figure 5.3 a & b). 
 
Figure 5.2. (a) Apparent kPL in Eµ-Myc cervical tumours before and after 




tumour with overlays of [1-13C]lactate/[1-13C]pyruvate ratio chemical shift images 
acquired between 20 and 50 s after [1-13C]pyruvate injection (b) before and (c) after 
treatment. The 13C MRS measurements in (a) were performed by Tiago Rodrigues 
and Mikko Kettunen.  
 
5.3.2. Whole-body [18F]FDG autoradiography of Eµ-Myc mice 
To determine whether the post-treatment [18F]FDG avid regions were tumour 
or normal tissue, whole body autoradiography was performed on Eµ-Myc mice and 
the autoradiograms co-registered with the H&E stained section (Figure 5.4). In 
addition to lymph node tumours, the salivary glands were sometimes infiltrated with 
tumour cells. 24 h after treatment with cyclophosphamide there was a dramatic 
reduction in lymph node volume, with an expansion of normal glandular tissue. The 
tumour/muscle ratio decreased from 2.71 ± 0.4 to 1.84 ± 0.55 (n = 4; P = 0.02) after 
treatment. Treatment did not significantly change [18F]FDG uptake in other tissues 
(2.21 ± 0.8 to 1.83 ± 0.5; n = 6; P = 0.07). The source of high [18F]FDG uptake (visible 
in the centre of both autoradiograms in Figure 5.4 a & c) was inconsistent: in most 
mice it appeared to be small areas of muscle but in others it appeared to be glandular 
tissue (probably sublingual gland).  
 There were two key implications of the [18F]FDG autoradiography: (1) [18F]FDG 
uptake in lymph node tumours does decrease in response to cyclophosphamide and 
(2) the area of high uptake most frequently corresponded to muscle and was probably 
also responsible for the spill-in effects seen with the larger ROI in the [18F]FDG-PET 
measurements acquired in vivo. Keeping mice anaesthetised throughout the uptake 




excluded if tumours could be better delineated by improving the soft tissue contrast of 
anatomical imaging187.  
Figure 5.3. The effect of ROI placement on [18F]FDG SUV. (a) A large post-
treatment ROI resulted in significant spill in from surrounding tissues, masking the 
decrease in tumour SUV. (b) A small ROI that avoided any of the high uptake areas 
showed a decrease in tumour SUV after treatment. Images of the cervical tumours of 
four mice are shown (c) before treatment; (d) after treatment showing examples of 






Figure 5.4. Eµ-Myc [18F]FDG autoradiography and co-registered H&E stained 
sections (a & b) before and (c & d) after treatment. Tissues 1 – 6 are shown at 
higher scale in the insets. (1) Sublingual gland; (2) submaxillary gland; (3) lymph node 
tumour; (4) submandibular gland with tumour infiltration; (5) lymph node tumour 24 h 
after treatment; (6) submandibular gland 24 h after treatment; (B) brain, in the pre-
treatment brain there was tumour cell infiltration as described previously189; (M) 
muscle. Black scale bars – 5 mm; white scale bars – 200 µm.  
 
5.3.3. Combined hyperpolarised [1-13C]pyruvate MRI and [18F]FDG-PET of Eµ-
Myc mice 
 Imaging with hyperpolarised [1-13C]pyruvate and [18F]FDG-PET was completed 
in eight mice, six of which were treated with cyclophosphamide 24 h before post-
treatment imaging with two acting as controls. Cyclophosphamide treatment resulted 
in a decrease in tumour volume from 1.23 ± 0.6 to 0.52 ± 0.2 cm3 (n = 6, P = 0.02). 




0.03) and [18F]FDG SUVmean decreased from 2.28 ± 0.4 to 1.28 ± 0.5 after treatment. 
Only in one animal did SUVmean not decrease but this was the only animal (including 
autoradiography cohorts) where there was an increase in tumour size following 
treatment. Anaesthesia throughout the imaging procedure limited the uptake in 
surrounding tissues and spill-in was greatly reduced compared to the previous imaging 
protocol.  
 The tumours of control mice behaved very similarly to treated mice. The tumour 
volume decreased from 1.28 ± 0.3 to 0.50 ± 0.1, labelled lactate/pyruvate ratio 
decreased from 2.86 ± 0.01 to 1.01 ± 0.4 and SUVmean decreased from 1.95 ± 0.1 to 





Figure 5.5. 3D reconstructions and axial slices through the cervical tumour of 
an Eµ-Myc mouse before (top) and after (bottom) cyclophosphamide treatment. 
Pre- and post-treatment images have the same scale, the CT is scaled from -1000 – 
3000 HU, and the [18F]FDG is scaled from an SUV of 0 – 2.5. The reduced background 





Figure 5.6. Changes in (a) tumour volume, (b) [1-13C]lactate/[1-13C]pyruvate 





5.3.4. T2-weighted imaging of control mice 
 Eµ-Myc mice were anaesthetised for 90 min and T2-weighted imaging of 
cervical tumours performed and repeated 48 h later. Tumour volume decreased by 63 
± 6% (n = 3) suggesting that the reduction in tumour volume seen in control mice was 
due to anaesthesia and animal handling, rather than as a result of CT irradiation or 
injection of [1-13C]pyruvate or [18F]FDG (Figure 5.7). 
 
Figure 5.7. The cervical tumour of an Eµ-Myc mouse imaged before and 48 h 




 This study investigated the combined use of hyperpolarised [1-13C]pyruvate 
and [18F]FDG-PET for detecting the response of Eµ-Myc cervical tumours to 
cyclophosphamide. In separate cohorts of mice cyclophosphamide caused a 69% 
decrease in 13C label exchange between pyruvate and lactate after 24 h. There was 
significant [18F]FDG uptake in tissues surrounding the tumour and, as indicated in a 




tumour specificity compared to [18F]FDG uptake182. This was presumably due to 
muscle having high rates of aerobic glycolysis but low rates of anaerobic lactate 
production and the lack of specificity that [18F]FDG uptake has for detecting the 
Warburg effect. This is potentially advantageous clinically although differentiating 
tumour and muscle is rarely an issue and it remains to be seen whether hyperpolarised 
[1-13C]pyruvate can differentiate tumours from inflammatory lesions which may also 
have increased rates of lactate production231. 
Whole body autoradiography showed that tumour [18F]FDG uptake decreased 
after treatment whilst uptake in surrounding normal tissues was largely unchanged. 
Furthermore, some of the most [18F]FDG avid tissues were areas of muscle and 
salivary gland. Due to the high morbidity of Eµ-Myc mice they were kept awake during 
the [18F]FDG uptake period, resulting in higher levels of background uptake, 
particularly by muscle187. Therefore, combined imaging with hyperpolarised [1-
13C]pyruvate and [18F]FDG was undertaken with mice anaesthetised throughout and, 
although this increased the mortality rate, a reduction in background [18F]FDG uptake 
made images far easier to interpret. Similar distributions of [1-13C]lactate production 
and [18F]FDG uptake were seen in all tumours before treatment. Cyclophosphamide 
caused mean decreases of 43%, 44%, and 57% in the labelled lactate/pyruvate ratio, 
SUVmean and tumour volume, respectively. In one animal tumour volume increased by 
41%, SUVmean increased by 19% and the labelled lactate/pyruvate ratio decreased by 
15% after cyclophosphamide treatment. However, in mice where both the tumour 
volume and SUVmean also decreased after treatment the labelled lactate/pyruvate ratio 
decreased by 54.2 ± 12%. Therefore, the slight decrease in the labelled 




Unfortunately, the study was limited by the sensitivity of the model to the stress 
of animal handling and anaesthesia as decreases of 65%, 42% and 61% were seen 
in labelled lactate/pyruvate ratio, SUVmean and tumour volume in untreated mice.  
  
5.5 Conclusions 
 In this study hyperpolarised [1-13C]pyruvate, [18F]FDG and tumour volume all 
showed responses to treatment in Eµ-Myc mice, although the response was not 
necessarily due to the cyclophosphamide treatment. Although anaesthetising animals 
throughout the [18F]FDG uptake period minimised background uptake, this study 
highlights the potential of measuring [1-13C]pyruvate to [1-13C]lactate flux as a more 
specific measure of the Warburg effect than [18F]FDG-PET.  
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6. Hyperpolarised [1-13C]pyruvate and [18F]FDG 
imaging for detecting cell death induced by a 







 The preceding two chapters comparing hyperpolarised [1-13C]pyruvate and 
[18F]FDG for detecting treatment response in two mouse tumour models came to 
differing conclusions. In murine EL4 tumours there was a reduction in [18F]FDG uptake 
but hyperpolarised [1-13C]pyruvate did not detect a response. However, there were 
variable levels of cell death before and after treatment that limited the study. In Eµ-
Myc mice both agents detected a response in tumours but control conditions also 
invoked a tumour response. In the work described in this chapter human colorectal 
(Colo205) and breast (MDA-MB-231) adenocarcinoma xenografts were treated with 
MEDI3039, a multivalent TRAIL agonist that activates the extrinsic pathway of 
apoptosis by targeting death receptor 5 (DR5). Although subcutaneous tumours in 
athymic Balb/c nude mice have clear limitations as models of human disease, they 
have the advantages of relatively rapid tumour growth (approximately 6 – 10 weeks), 
minimal pre-treatment cell death and rapid, extensive apoptosis following MEDI3039 
treatment. Furthermore, both cell lines were engineered to express luciferase and 
mStrawberry fluorescent protein to provide independent measures of treatment 
response.  
Combined hyperpolarised [1-13C]pyruvate and [18F]FDG-PET imaging was 
performed to detect the early response of Colo205 and MDA-MB-231 tumours 24 h 
after treatment with MEDI3039, which induced long-term tumour remission232. There 
was a reduction in label flux between hyperpolarised [1-13C]pyruvate and [1-
13C]lactate in all animals after treatment. This was accompanied by a decrease in 
bioluminescence but preceded by a reduction in tumour volume. In the same cohort 
[18F]FDG-PET largely failed to detect response. Using a novel fluorescence activated 




cell infiltration or activation. We demonstrated that glucose and [18F]FDG continued to 
accumulate and be phosphorylated in treated tumours but there was a decrease in 
further metabolism. These results indicate that in certain tumours hyperpolarised [1-
13C]pyruvate may be a more sensitive marker of response to treatment than [18F]FDG.  
 
6.2. Methods 
The following methods described in “Chapter 2 - Methods” are used in this chapter: 
2.1. Animal licence statement 
2.3.  Colo205 cell culture, tumour growth and treatment 
2.4.  MDA-MB-231 cell culture, tumour growth and treatment 
2.6.  Anaesthesia of mice 
2.7.  Hyperpolarisation of [1-13C]pyruvate 
2.8.  Western blotting 
2.9.  Lactate dehydrogenase (LDH) activity assay 
2.10.  Immunohistochemistry (IHC) 
2.11.  Statistical analysis 
 
6.2.1. Animal preparation 
Mice were fasted for 6 – 8 h and kept in a warmed chamber (31 ºC) for 1 h prior 
to anaesthesia before all procedures requiring intravenous injection or imaging187, 233.  
 
6.2.2. Detection of long-term treatment response 
 Colo205 tumour-bearing mice (n = 3) were treated with MEDI3039 i.v. weekly 




(for 72 h), T2-weighted MRI (for 12 days), fluorescence and bioluminescence imaging 
(for 176 days). 
 
6.2.3. Imaging treatment response 
Mice were warmed, anaesthetised and a tail vein cannula inserted as described 
previously. Venous glucose concentration was measured using a StatStrip Xpress 
glucose meter (Nova Biomedical, Waltham, MA, USA). Bioluminescence, 
fluorescence, MRI and PET-CT imaging were performed in the same 2 h session 
before and 24 h after treatment with MEDI3039. Fluorescence and bioluminescence 
imaging were performed using an IVIS Lumina In Vivo Imaging System (Perkin Elmer, 
MA, USA). Fluorescence images (FLI) of mStrawberry expression (wavelength of 
excitation (λex) = 574 nm, wavelength of emission (λem) = 596 nm) were obtained using 
a DSRed filter (λex = 500-550 nm, λem = 575-650 nm) and corrected for background 
autofluorescence. Bioluminescence images (BLI) were acquired 5 min after 
intraperitoneal injection of 150 mg/kg D-luciferin.  
After completion of bioluminescence imaging, mice were injected intravenously 
with 12.9±1.8 MBq [18F]FDG (Alliance Medical, Guildford, UK) before magnetic 
resonance imaging (MRI). MRI was performed in a 7.0 T horizontal bore magnet 
(Agilent, Palo Alto, CA) using an actively decoupled dual-tuned 13C/1H volume transmit 
coil (Rapid Biomedical, Rimpar, Germany) and a 20 mm diameter 13C receiver coil 
(Rapid Biomedical) placed over the tumours. To facilitate co-registration between PET 
and MR images the receiver coil and hindquarters of the mice were fixed to the mouse 
bed using R&S Turboflex (CFPM, Aulnay-sous-Bois, France). For anatomical 
reference, eight axial T2-weighted 1H images were acquired using a fast-spin echo 




size of 256 × 256 points. 13C images were acquired using a SpSp pulse sequence and 
3D DSE acquisition.223 Flip angles were 7º for [1-13C]pyruvate and 45º for [1-
13C]lactate, respectively, FOV was 40 × 40 × 20 mm  with a nominal spatial resolution 
of 1.25 × 1.25 × 2.5 mm in the x, y and z planes, respectively. Five [1-13C]pyruvate 
images were acquired prior to the first [1-13C]lactate image, after which each 
metabolite was excited at a temporal resolution of 2 s per metabolite. At 1 h after 
injection of [18F]DG, hyperpolarised [1-13C]pyruvate (15 mL/kg) was infused 
intravenously over 8 s and the pulse sequence was started 2 s after the start of the 
infusion. Five [1-13C]pyruvate images were acquired prior to the first [1-13C]lactate 
image in order to minimise off-resonance effects and maximise SNR. Images were 
acquired over 90 s and analysed in MATLAB (Mathworks, MA, USA). A 3D region of 
interest (ROI) over the tumour was defined on the T2-weighted image and the [1-
13C]lactate/ [1-13C]pyruvate signal ratio was calculated from the area under the curve 
of their respective time courses.  
After completion of MRI the bed with mouse in situ was transferred to a 
nanoScan PET/CT (Mediso, Budapest, Hungary).  A 15 min static PET acquisition 
began at 90 min post-injection of [18F]FDG. Static PET images, with a nominal isotropic 
resolution of 0.3 mm, were reconstructed using a 3D ordered-subset expectation 
maximisation method with one to three coincidence mode, eight iterations and six 
subsets. Images were normalised and corrected for decay, dead-time, random events 
and attenuation. For anatomical reference and attenuation correction a whole-body 
helical CT was acquired with 360 projections, 55 kVp x-ray energy, 600 ms exposure 
time and 0.21 mm isotropic voxels.  The images were analysed using Vivoquant 3.0 




over the subcutaneous tumour and Otsu thresholding applied to delineate the tumour. 





where cimg is the activity concentration (MBq/mL) derived from the image ROI, ID is 
the injected dose and BW is the body weight of the animal.  
 
6.2.4. Dynamic contrast enhanced (DCE) MRI  
A separate cohort of Colo205 tumour-bearing mice (n = 3) was used to acquire 
a DCE-MRI dataset, before and 24 h after treatment with MEDI3039. Baseline spin-
lattice relaxation rates (R1,pre =1/T1) were measured using an inversion recovery fast 
low angle shot (FLASH) pulse sequence (TR 5.5 ms, TE 2.5 ms, 10 s delay between 
acquisitions, 2 averages per inversion time). To obtain a pre-contrast R1 map these 
data were fitted voxel-by-voxel to a mono-exponential function: 
S = S0[1 – 2 e-TI/T1] 
 where TI is the inversion time. A T1-weighted gradient-echo pulse sequence was used 
with 4 × 1.5 mm thick axial slices with 0.25 mm gaps covering the tumour region, FOV 
40 × 40 mm, data matrix 128 × 128, TR 110 ms, TE 9 ms. Ten baseline images were 
collected prior to the injection, over 8 s, of 200 μmoles/kg i.v. Dotarem® (gadoterate 
meglumine; Guerbet, Villepinte, France). Forty images were acquired immediately 
after injection and a further nine blocks of nine images were acquired every ten 
minutes up to 90 min post-injection. Each block of nine images were averaged, 
creating the timepoints in Figure 6.5. Images were converted to R1 relaxation rate 
maps using:  







where S0 is the relaxed signal (TR >> T1) and θ is the flip angle used in the gradient-
echo sequence (27º). Changes in R1 were directly converted to gadolinium (Gd3+) 
concentration curves as described by Noebauer-Huhmann et al.234. The DCE 
calculations were performed by Alan Wright.  
 
6.2.5. Dynamic [18F]FDG-PET imaging 
 A separate cohort of Colo205 tumour-bearing mice (n = 9) was imaged before 
and 24 h after treatment with MEDI3039. Mice were imaged three at a time. A 3 h PET 
acquisition was started just prior to injection over 30 s of 8.12 ± 1.13 MBq [18F]FDG 
into each tumour-bearing mouse. Data were acquired in list-mode format. A CT image 
was acquired for anatomic co-registration and attenuation correction. Scans were 
reconstructed with a nominal isotropic resolution of 0.6 mm using a 3D ordered-subset 
expectation maximisation method with one to five coincidence modes, two iterations 
and six subsets. Images were normalised and corrected for decay, dead-time, random 
events and attenuation. Three h scans were reconstructed into 50 time frames (5 s × 
12, 0 – 1 min; 2 min × 30, 0 – 60 min; 15 min × 8, 60 – 180 min). An image-derived 
arterial input function was derived from a 3D ROI drawn manually over the aorta and 
inferior vena cava (which could not be differentiated from each other). To minimise 
spill-in effects the ROI was drawn between the level of the kidneys and diaphragm, 
where contributions from other organs are relatively low, and thresholded at 75% of 
the maximum in the 5 s time frames. A 3D ROI drawn manually over the tumour was 
Otsu thresholded on the 165 – 180 min dataset. Patlak graphical analysis was used 
to estimate the rate of irreversible [18F]FDG uptake (ki) from the linear portion of the 
graph between 20 and 60 min209. Across all datasets, the mean coefficient of 




6.2.6. Whole-body [18F]FDG autoradiography and mStrawberry fluorescence 
imaging 
Colo205 tumour-bearing mice (n = 6) were anaesthetised and injected 
intravenously with [18F]FDG, sacrificed by cervical dislocation at 90 min post-injection 
and immediately frozen by submersion in a bath of isopentane surrounded by an outer 
liquid nitrogen bath. Ten µm-thick axial cryo-sections (CM3050S Cryostat, Leica) were 
thaw-mounted onto microscope slides. Fluorescence images (Amersham™ 
Typhoon™ Biomolecular Imager) of mStrawberry distribution were acquired using a 
532 nm laser and long-pass 550 nm filter with a pixel size of 10 µm. Slides were then 
placed adjacent to a storage phosphor screen (GE) overnight and imaged with a pixel 
size of 10 µm. The slides were subsequently H&E stained and the three images (red 
fluorescence, autoradiography and H&E images) were co-registered manually.  
 
6.2.7. Determining the cellular fate of [18F]FDG using fluorescence-activated cell 
sorting (FACS) 
Colo205 tumour-bearing mice (n = 6) were anaesthetised and injected 
intravenously with 140 ± 4.9 MBq [18F]FDG. At 90 min post-injection, the animals were 
sacrificed by cervical dislocation and the tumours removed, weighed and washed in 
PBS. Single cell suspensions were prepared by finely mincing the tumours and 
digesting them in 1 mg/mL collagenase I (Sigma-Aldrich, MO, USA) and 0.1 mg/mL 
DNase I (Roche, Penzburg, Germany) at 37 ºC for 45 min with trituration at 15 min 
intervals. The cells were washed in PBS / 2mM EDTA and labelled for flow cytometry 
by incubation with anti-CD45 (30-F11), anti-CD11b (M1/70) (Biolegend, CA, USA) and 
live/dead fixable viability dye e780 (eBioscience, ThermoFisher Scientific, MA, USA) 




CD45- / mStrawberry- non-haematopoetic, non-tumour cells and e780+ dead cells 
were sorted on a BD Influx™ flow sorter (BD Biosciences, NJ, USA). Flow cytometric 
data were analysed using FlowJo V10.0 (FlowJo LLC, OR, USA). The activity (cpm) 
of each cell population was counted three times for five minutes on a well counter 
(Nuklear-Medizintechnik, Dresden, Germany) and converted to Bq using a calibration 
curve and the injected dose per cell calculated.  
 
6.2.8. [1,6-13C2]glucose infusion and 13C and 1H NMR spectroscopy of tumour 
extracts 
 Colo205 tumour-bearing mice were anaesthetised and [1,6-13C2]glucose 
infusions were performed as described previously235. Mice were sacrificed by cervical 
dislocation and the tumours immediately freeze-clamped in liquid nitrogen-cooled 
tongs and blood obtained by cardiac puncture. Extracts were prepared by the addition 
of 5 µL/mg tissue 2 M perchloric acid (PCA) and homogenisation using a Precellys 24 
homogeniser (Stretton Scientific, Stretton, UK). Extracts were pH corrected to 7.0 with 
2 M KOH, lyophilised and dissolved in 99.9% deuterium oxide. Two µmoles 
trimethylsilylpropanoic acid (TMSP) were added to each sample as a chemical shift 
standard (0 p.p.m.). High-resolution 1H and 1H-decoupled 13C NMR spectra were 
acquired at 294 K using a Bruker 600 MHz NMR spectrometer (Bruker, MA, USA) 
using a 5 mm probe. 13C spectroscopy acquisition used a pulse-acquire sequence with 
30º flip angle, 15000 transients, spectral width 36.8 kHz, acquisition time 1.8 s and a 
relaxation delay 1.2 s. 1H spectroscopy used a pulse-acquire sequence with a 90º flip 
angle, 1024 transients, spectral width 10 kHz, acquisition time 3.3 s, relaxation delay 
2 s. Data were phased and baseline-corrected and peak areas calculated using 




6.2.9. Analysis of [18F]FDG and labelled metabolites in tumour extracts 
 Colo205 tumour-bearing mice were anaesthetised and injected, via a tail vein, 
with a bolus of 146.2 ± 7.8 MBq [18F]FDG. After 90 min the mice were sacrificed by 
cervical dislocation and the tumours excised and immediately homogenised in ice-cold 
4M PCA using a Precellys homogeniser (Stretton Scientific, Stretton, UK). The 
extracts were neutralised using 8M KOH and passed through an Anotop 10, 0.2 μm 
syringe filter (Whatman, Maidstone, UK). RadioHPLC was performed using a Dionex 
UltiMate 3000 HPLC system (ThermoFisher Scientific, MA, USA) using a method 
adapted from Rokka et al.236. 100 μL samples were injected into the system, separated 
using a Partasil SAX 10 μm column (250 mm × 4.6 mm, Sigma-Aldrich) and eluted 
with a linear gradient of 300 mM sodium dihydrogen phosphate containing 2% 
methanol (A) and 2% methanol in water (B). The gradient profile was 0 – 15 min 5% 
A, 15 – 25 min 50% A (isocratic), with a flow rate of 1.5 ml/min. Radioactivity was 
detected using a fLumo HPLC NaI detector (Berthold Technologies, Bad Wildbad, 
Germany) connected to the outflow of the column. Data were collected and analysed 
using Chromeleon v6.8 (ThermoFisher Scientific, MA, USA). Metabolites had the 
following retention times: 2 min, [18F]FDG; 6 min, [18F]FDG-6-P; 20 min, 2-([18F]fluoro)-
2-deoxy-6-phospho-D-gluconolactone [18F]FD-PGL; and 22.5 min, 2-([18F]fluoro)-2-
deoxy-D-glucose-1,6-bisphosphate ([18F]FDG-1,6-P2). 
 
6.2.10. ATP quantification assay 
 Tumour ATP concentration was quantified from freeze-clamped tumour 
samples using a colourimetric ATP Assay Kit (ab83355, Abcam, Cambridge, UK). 
Absorbance at 570 nm was measured using a PHERAstar FS microplate reader (BMG 





6.3.1. MEDI3039 induces cell death and tumour regression 
 MEDI3039 treatment of Colo205 tumour-bearing mice (n = 3) resulted in a 
decrease in tumour volume from 0.95±0.1 cm3 to 0.03±0.02 cm3 12 days after initial 
treatment, after which volumes dropped to below the detection limit for T2-weighted 
MRI (Figure 6.1 a – d). After treatment, bioluminescence and red fluorescence 
intensity decreased over the first month, after which one tumour started to regrow 
while the other two continued to decrease in intensity (Figure 6.1 e – n). Animals were 
culled at six months, at which point the tumour that regrew had reached its size limit 
and in the other two mice the tumours remained undetectable.  
 
Figure 6.1. MEDI3039 treatment induces long-term remission of Colo205 
tumours. (a-d) Tumour volumes (n=3) were determined by T2-weighted MRI 
measurements. (e-h) mStrawberry fluorescence; (j-n) bioluminescence. The 
bioluminescence scale has been decreased by a factor of 10 for the images acquired 





6.3.2. Histological evaluation of cell death in tumours treated with MEDI3039 
 Colo205 (n = 18) and MDA-MB-231 (n = 22) tumour-bearing mice underwent 
combined BLI, FLI, [1-13C]pyruvate MRI and FDG-PET imaging before and 24 h after 
treatment with either MEDI3039 or drug vehicle (Table 6.1). After treatment an 
insignificant increase in tumour volume was observed in controls for both tumour types 
while there was a slight, insignificant decrease in the volume of tumours treated with 
MEDI3039 (Figure 6.2). Treatment resulted in a significant increase in CC3 staining 
from 21.8 ± 11.6% to 58.51 ± 14.4% (P = 0.0002) in Colo205 tumours and 19 ± 5.1% 
to 57.7 ± 19.3% (P = 0.006) in MDA-MB-231 tumours. TUNEL staining increased from 
8.0 ± 6.7% to 19.4 ± 6.3% (P = 0.007) in Colo205 tumours and 6.6 ± 2.0% to 21.1 ± 




Table 6.1. Multi-modality imaging and histological detection of treatment 
response 24 h after administration of 0.4 mg/kg MEDI3039. Levels of significance: 
*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.  
 
 mStrawberry fluorescence decreased in response to treatment in MDA-MB-231 
tumours by 45.3 ± 28.6% (P = 0.0002) but there was no change in Colo205 tumours 
(P = 0.30). However, fluorescence in these tumours had started to decrease by 48 h 
after treatment (P = 0.04; n = 3). With the exception of one animal, bioluminescence 
decreased after treatment, with a 57.3 ± 53.3% (P = 0.0053; n = 10) and 68.5 ± 24.8% 
(P = <0.0001; n = 12) decrease in Colo205 and MDA-MB-231 tumours, respectively. 
 T2 MRI Bioluminescence Fluorescence 13C MRI 




Mean Radiant Efficiency 
([p/s/cm2/sr] / [µW/cm2]) 
[1-13C]lactate / 
[1-13C]pyruvate ratio 
Colo205     
Pre-treatment 0.879 ± 0.425  (n = 10) 
2.455 × 109 ± 3.445 × 109 
(n = 10) 
1.465 × 109 ± 9.009 × 108  
(n = 8) 
2.525 ± 0.549  
(n = 7) 
Post-treatment 0.829 ± 0.491  (n = 10) 
4.723 × 108 ± 5.678 × 108 
** (n = 10) 
2.068 × 109 ± 1.981 × 109  
(n = 8) 
1.414 ± 0.391  
** (n = 7) 
Pre-control 
0.705 ± 0.252  
(n = 7) 
6.961 × 108 ± 9.705 × 108 
(n = 8) 
1.373 × 109 ± 1.494 × 109  
(n = 7) 
1.975 ± 0.548  
(n = 5) 
Post-control 0.721 ± 0.289  (n = 7) 
1.092 × 109 ± 1.406 × 109 
(n = 8) 
1.288 × 109 ± 1.191 × 109  
(n = 7) 
2.106 ± 0.630  
(n = 5) 
MDA-MB-231     
Pre-treatment 0.939 ± 0.488  (n = 8) 
1.288 × 109 ± 4.629 × 108 
(n = 12) 
3.002 × 109 ± 1.180 × 109  
(n = 12) 
2.236 ± 0.386  
(n = 7) 
Post-treatment 0.862 ± 0.450  (n = 8) 
4.148 × 108 ± 4.340 × 108 
**** (n = 12) 
1.634 × 109 ± 1.015 × 109  
*** (n = 12) 
1.382 ± 0.331  
** (n = 7) 
Pre-control 0.664 ± 0.281  (n = 9) 
1.541 × 109 ± 1.503 × 109 
(n = 9) 
2.349 × 109 ± 1.067× 109  
(n = 9) 
2.126 ± 0.588  
(n = 9) 
Post-control 0.686 ± 0.304  (n = 9) 
1.067 × 109 ± 6.385 × 108 
(n = 9) 
2.174 × 109 ± 1.110 × 109  
(n = 9) 
2.442 ± 0.607  
(n = 9) 
 [
18F]FDG-PET Histology 
Tumour type SUVmax SUVmean ki CC3 (% positivity) 
TUNEL 
(% positivity) 
Colo205      
Pre-treatment 2.103 ± 0.250  (n = 7) 
1.131 ± 0.160  
(n = 7) 
0.048 ± 0.01 
(n = 9) 
  
Post-treatment 2.134 ± 0.362  (n = 7) 
1.087 ± 0.190  
(n = 7) 
0.037 ± 0.012 
(n = 9) 
58.510 ± 14.440 
*** (n = 7) 
19.360 ± 6.311 
** (n = 7) 
Pre-control 2.261 ± 0.580  (n = 7) 
1.230 ± 0.223  
(n = 7) 
   
Post-control 2.219 ± 0.161  (n = 7) 
1.182 ± 0.206  
(n = 7) 
 21.800 ± 11.580 
(n = 7) 
8.005 ± 6.728 
(n = 7) 
MDA-MB-231      
Pre-treatment 2.219 ± 0.399  (n = 10) 
1.045 ± 0.172  
(n = 10) 
   
Post-treatment 1.977 ± 0.346  (n = 10) 
0.877 ± 0.158 *  
(n = 10) 
 57.650 ± 19.300 
** (n = 5) 
21.120 ± 6.061 
** (n = 5) 
Pre-control 2.125 ± 0.558  (n = 9) 
0.998 ± 0.214  
(n = 9) 
   
Post-control 2.039 ± 0.685  (n = 9) 
0.913 ± 0.275  
(n = 9) 
 18.980 ± 5.092 
(n = 4) 
6.644 ± 1.944 




Corresponding to the decrease in bioluminescence signal, measurements of ATP 
concentrations in Colo205 tumour extracts showed a decrease from 0.36 ± 0.1 to 0.14 
± 0.05 μmol/g w.w. (P = 0.0008; n = 11) at 24 h after treatment.  
  
Figure 6.2. Tumour volume measurements of (a) Colo205 and (b) MDA-MB-231 





Figure 6.3.  Histological assessment of tumour cell death following treatment 
with MEDI3039.  Tumour sections were stained for cleaved caspase 3 (CC3) and 
TUNEL. (a – c) CC3 and (g – j) TUNEL staining of Colo205 tumour sections taken 24 
h after treatment of the animals with MEDI3039 (treatment) or drug vehicle (control).  
(d – f) CC3 and (g – j) TUNEL staining of MDA-MB-231 tumour sections taken 24 h 




6.3.3. Imaging early response to MEDI3039 treatment using 13C MRI and 
[18F]FDG-PET 
 3D 13C MR images, following injection of hyperpolarised [1-13C]pyruvate, 
showed a post-treatment reduction of the [1-13C]lactate/[1-13C]pyruvate ratio in all 
animals, with a mean reduction of 42.2 ± 15.9% (P = 0.004; n = 7) and 36.3 ± 18.6% 
(P = 0.007; n = 7) in Colo205 and MDA-MB-231 tumours, respectively (Table 1 and 
Figure 6.4). However, with [18F]FDG-PET there was no change in SUVmax (2.1 ± 0.3 
to 2.1 ± 0.4, P = 0.82) or SUVmean (1.1 ± 0.2 to 1.1 ± 0.2, P = 0.6) in Colo205 tumours 
after treatment. In a separate cohort of Colo205 tumours there was an insignificant 
decrease in influx rate constants for [18F]FDG after treatment (0.05 ± 0.01 to 0.04 ± 
0.01, P = 0.052). In MDA-MB-231 tumours SUVmax did not change significantly (2.2 ± 
0.4 to 2.0 ± 0.3, P = 0.2) but there was a decrease in SUVmean (1.0 ± 0.2 to 0.9 ± 0.2; 
P = 0.05) after treatment. However, this was a decrease of 14 ± 21%, compared to a 
36 ± 19% decrease in [1-13C]lactate/[1-13C]pyruvate ratio in the same tumours, 
indicating that changes in [1-13C]pyruvate metabolism were more sensitive for 
detecting response to treatment in these tumours. 
 To determine whether there were later changes in [18F]FDG uptake, Colo205 
tumour-bearing mice (n = 3) were imaged 24, 48 and 72 h following MEDI3039 
treatment. Mean SUVmax increased insignificantly from 1.67 ± 0.1 before treatment to 
1.79 ± 0.5 (P = 0.77) 72 h after treatment, despite significant decreases in tumour 






Figure 6.4. Comparison of hyperpolarised [1-13C]lactate/[1-13C]pyruvate ratio 
and [18F]FDG-PET SUVmax in Colo205 and MDA-MB-231 tumours before and 24 
h after treatment with MEDI3039. (a) A Colo205 tumour-bearing mouse before (top 
two rows of images) and after treatment (bottom two rows of images). 3D metabolite 
images overlaid on bone reconstructions (top and bottom rows) and an axial slice 
through the tumour (middle two rows). The tumour is indicated by white arrows and a 
dashed outline. (b & d) [1-13C]lactate/[1-13C]pyruvate ratio before and after treatment 
in (b) Colo205 and (d) MDA-MB-231 tumours. (c & e) [18F]FDG SUVmax before and 




6.3.4. DCE-MRI shows an increase in Colo205 tumour perfusion after MEDI3039 
treatment 
 In a separate cohort of Colo205 tumour-bearing mice (n = 3) treatment 
response was assessed using DCE-MRI measurements (Figure 6.5). Tumour 
gadolinium (Gd3+) concentration increased in all mice after treatment from 0.05 ± 0.009 
to 0.09 ± 0.02 mM at 10 min post-injection although, due to the low cohort size, this 
was not statistically significant. The rate of contrast agent clearance was similar in pre-
treatment and post-treatment tumours.  
 
Figure 6.5. Dynamic contrast enhanced MRI in Colo205 tumours before and 24 
h after treatment with MEDI3039.  
 
6.3.5. Autoradiography of [18F]FDG uptake in Colo205 tumours  
 To confirm the in vivo [18F]FDG-PET measurements, whole-body 
autoradiography of Colo205 tumour-bearing mice (n = 3, treated and untreated) was 
performed. [18F]FDG tumour/muscle ratios were unchanged after treatment (4.1 ± 0.8 
before treatment and 4.1 ± 0.6 after treatment, P = 0.9) (Figure 6.6). Measurements 
of [18F]FDG radioactivity in excised Colo205 tumours revealed a non-significant 
decrease of mean % injected dose per gram (%ID/g) from 8.8 ± 2.0 to 7.6 ± 1.7 after 






Figure 6.6. Ex vivo confirmation that [18F]FDG uptake was similar before and 24 
h after treatment. Examples of whole-body autoradiography sections of Colo205 
tumour-bearing mice 24 h before (a – c) and after MEDI3039 treatment (d – f). (a & d) 
whole-body [18F]FDG autoradiography; (b & e) mStrawberry fluorescence and (c – f) 
H&E staining of the same sections. (g) Tumour to muscle ratios derived from 
autoradiography (n = 3, colours indicate biological replicates, points indicate technical 
replicates from different sections); (h) uptake of [18F]FDG measured in excised 
tumours. Abbreviations: ID – injected dose.  
 
6.3.6. Determining the cellular fate of [18F]FDG using FACS 
 Before treatment (n = 3) tumour cells (mStrawberry+, CD45-) comprised 78.3 
± 5.2% of the cells sorted by flow cytometry, a figure that dropped to 71.6 ± 9.4% (n = 
3, P = 0.3) in tumours 24 h after treatment with MEDI3039 (Figure 5.7). In contrast, 
phagocytes (CD45+, CD11b+) comprised just 1.6 ± 0.4% of cells prior to treatment 




decrease in [18F]FDG uptake (%ID/cell) in tumour cells from 2.1 × 10-9 ± 5.0 × 10-10% 
to 7.5 × 10-10 ± 2.7× 10-10% (P = 0.01). Phagocytes were by far the most [18F]FDG avid 
cell-type, taking up 1.2 × 10-8 ± 2.5 × 10-9% per cell before treatment, which was 
approximately 5× tumour cell uptake. As in tumour cells after treatment, the activity 
per phagocyte also decreased to 6.5 × 10-9 ± 1.9 × 10-9 (P = 0.04) and was 
approximately 8× the uptake of tumour cells. However, due to there being 
approximately 50× and 30× more tumour cells than phagocytes before and after 
treatment, respectively, despite their greater [18F]FDG uptake per cell, the contribution 
of phagocytes to [18F]FDG uptake in the tumour as a whole remained small. Correction 
for % cell type, represented as %ID per million total cells, showed that before treatment 
uptake in the tumour cell population was 2 × 10-3 ± 5 × 10-4% per million cells, whereas 
in phagocytes it was 2 × 10-4 ± 8.7 × 10-5% per million cells. After treatment uptake in 
the tumour cell population was 6 × 10-4 ± 5.5 × 10-4%, whereas in the phagocyte 





Figure 6.7. FACS sorting of ex vivo Colo205 tumours and determination of the 
cellular fate of [18F]FDG.  Examples of sort profiles of tumours 24 h after treatment 
with (a) drug vehicle and (b) MEDI3039; (c) the percentage of different cell types 
sorted; (d) the percentage injected dose per cell for each cell type and (e) the 
percentage injected dose for each population of cells (i.e. the %ID per cell corrected 





6.3.7. Measurement of glycolytic flux in MEDI3039-treated Colo205 tumours 
using [1,6 13C2]glucose infusions 
 To investigate the effect of treatment on glycolytic flux [1,6 13C2]glucose was 
infused into mice (n = 3, treated and untreated). At the end of each 150 min infusion 
of [1,6 13C2]glucose 13C enrichment of blood glucose was 50.0 ± 7.2%. There was no 
difference in the enrichment between treated and untreated animals. The 
concentration of [3-13C]lactate, measured in extracts of Colo205 tumours, decreased 
from 1259 ± 297 μmoles/g w.w. before treatment to 363 ± 148 μmoles/g w.w. after 
treatment (P = 0.01, Figure 6.8). Treatment also resulted in a decrease in [3-
13C]alanine and [4-13C]glutamate labelling. There was a much smaller and non-
significant decrease in [1,6 13C2]glucose concentration in the tumours, from 425 ± 169 





Figure 6.8. 13C NMR measurements of Colo205 tumour extracts following [1,6 
13C2]glucose infusions into tumour-bearing mice 24 h after drug vehicle or 
MEDI3039 treatment. Example 13C NMR spectra from (a) a control tumour and (b) a 
treated tumour. Chemical shift assignments: 1, β-glucose C1; 2, α-glucose C1; 3, β-
glucose C6; 4, α-glucose C6; 5, lactate C3; 6, alanine C3. Insets: the spectra zoomed 
between 30 and 37 p.p.m. to show the difference in C3 and C4 glutamate labelling 
before treatment and after treatment. (c) Diagram showing the 13C labelling pattern 
(blue) following [1,6 13C2]glucose infusions. (d) Comparison of 13C labelled glucose 





6.3.8. MEDI3039 induced changes in the expression of glycolytic enzymes and 
membrane transporters in Colo205 tumours  
Tumour protein expression of the enzymes and transporters involved in [18F]FDG 
uptake and [1-13C]pyruvate uptake and metabolism to [1-13C]lactate were investigated 
by western blotting (Table 6.2, Figure 6.9). Treatment resulted in decreased 
expression of both monocarboxylate transporters, MCT1 and to a lesser extent MCT4 
(P = 0.005 and P = 0.02, respectively). LDH activity and expression were unchanged, 
(P = 0.07 and P = 0.9, respectively) (Table 6.3). Expression of GLUT1 and GLUT3 
also decreased (P = 0.01 and P = 0.0001, respectively), while HK2 expression was 
unchanged (P = 0.1). PARP cleavage by caspase-3, a feature of apoptosis and 
previously correlated with NADH depletion and subsequent reduction in pyruvate to 
lactate exchange in vitro, increased significantly after MEDI3039 treatment (P = 
0.005)69, 107.  
 
Table 6.2. Protein expression of the transporters and enzymes involved in 
[18F]FDG and [1-13C]pyruvate uptake and metabolism in Colo205 tumours. 
Numbers are level of expression relative to: GAPDH for MCT1; β-tubulin for MCT4 




Table 6.3. Enzyme activities in Colo205 tumours. All enzyme activities are 
expressed in units/mg protein.  
Treatment MCT1 MCT4 GLUT1 GLUT3 LDH HK-2 cPARP 
Control 
(n = 7) 
0.070 ± 0.01 
 
0.47 ± 0.04 
 
0.028 ± 0.007 
 









(n = 7) 
0.013 ± 0.009 
** 
0.32 ± 0.04 
* 
0.0079 ± 0.002 
* 








Treatment LDH activity GAPDH activity PK activity 
Control (n = 7) 2.1 ± 0.3 0.16 ± 0.1 2.4 ± 1.6 





Figure 6.9. Expression and enzyme activity changes induced by MEDI3039 
treatment. Arrows above western blots indicate post-treatment tumours. (a) MCT1 
expression; (b) MCT4 expression; (c) LDH-A expression; (d) LDH activity; (e) GAPDH 
activity; (f) GLUT1 expression; (g) GLUT3 expression; (h) HK2 expression; (j) PARP 
expression; (k) pyruvate kinase activity. Abbreviations: cPARP – cleaved PARP; 




Given the discrepancy between [18F]FDG uptake and lactate production in tumours, 
the activity of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and pyruvate 
kinase (PK) were measured but treatment did not change activity of either these 
glycolytic enzymes. 
 
6.3.9. Measurement of [18F]FDG and its metabolites in tumour extracts 
 As [1,6 13C2]glucose could not be differentiated from [1,6 13C2]glucose-6-
phosphate using NMR, HPLC measurements on tumour extracts were used to 
determine whether treatment affected [18F]FDG phosphorylation (Figure 6.10). In 
Colo205 tumours >90% of [18F]FDG was phosphorylated regardless of MEDI3039 
treatment. The ratio of [18F]FDG/[18F]FDG-6-P was 6.2 ± 3% prior to treatment and 7.0 
± 3.7% after treatment (n =3, P = 0.8). In addition to [18F]FDG and [18F]FDG-6-P peaks 
at retention times of 2 and 6 min respectively, we observed peaks at 8.5, 9, 20 and 
22.5 min. The peak at 20 min, assigned to [18F]FD-6-PGL236, was reduced in treated 






Figure 6.10. RadioHPLC measurements of [18F]FDG metabolism in Colo205 
tumours 24 h after control or MEDI3039 treatment. Examples of radioHPLC 
chromatograms from (a) a control tumour and (b) a MEDI3039 treated tumour.  (c) 
Comparison of [18F]FDG/[18F]FDG-6P ratios in control and MEDI3039 treated tumours. 







 Earlier detection of treatment response is one of the most likely clinical 
applications of hyperpolarised [1-13C]pyruvate110, 111. Previous pre-clinical studies in 
models of breast cancer and glioma have demonstrated reductions in label flux from 
[1-13C]pyruvate to lactate prior to a reduction in tumour volume161, 169. However, others 
have failed to demonstrate the superiority of hyperpolarised [1-13C]pyruvate over 
reductions in tumour volume or [18F]FDG uptake69, 107, 173.  
 Cytotoxic chemotherapeutic agents can have direct effects on metabolic 
pathways, for example, etoposide is known to inhibit oxidative phosphorylation220, 237. 
Therefore, any effects observed with metabolic imaging may be drug-specific, rather 
than a generic measure of treatment response. The aim of this study was to use a 
targeted agent to induce apoptosis which avoided potential direct effects of the drug 
on glycolytic enzyme expression and allowed comparison of hyperpolarised [1-
13C]pyruvate and [18F]FDG to provide a generic marker of treatment response in the 
colorectal (Colo205) and breast (MDA-MB-231) xenograft models. As reported 
previously, MEDI3039 was highly effective at inducing apoptosis in tumours with no 
detectable side effects232, 238. In two out of three tumours treatment increased survival 
from under two weeks in control animals to a minimum of six months in treated mice. 
To study early detection of treatment response we used 24 h as the earliest possible 
timepoint between repeated i.v. cannulations and anaesthesia sessions. At 24 h after 
treatment there were marked increases in histological markers of cell death (CC3 and 
TUNEL staining), decreased mStrawberry fluorescence in MDA-MB-231 tumours and 
reductions in bioluminescence in both tumour types, indicating a loss of ATP, which 
was confirmed in tumour extracts. In both tumour types label flux from hyperpolarised 




changes in tumour volume. Decreased labelling can be explained by decreased MCT1 
and MCT4 expression and a reduction in the size of the lactate pool160. 
 The failure to observe a significant decrease in [18F]FDG uptake in treated 
tumours was surprising given the degree of cell death observed histologically. 
Although we observed significant decreases in GLUT1 and GLUT3 expression, HK2 
expression did not change and there was a slight increase in perfusion after treatment. 
The relationship between [18F]FDG accumulation in tissues is multi-factorial and poorly 
understood, with studies not demonstrating a consistent relationship between 
[18F]FDG uptake and GLUT and hexokinase expression67, 71. Here 13C NMR 
measurements of [1,6 13C2]glucose metabolism and radioHPLC measurements of 
[18F]FDG metabolism showed that treatment of Colo205 tumours reduced glycolytic 
flux to lactate, flux into the TCA cycle and PPP but that phosphorylation of [18F]FDG 
was maintained. This suggests that, contrary to the generally accepted view, 
[18F]FDG-6-P accumulation in tumours is not necessarily reflective of glycolytic flux 
and that the differential response seen with [18F]FDG-PET and [1-13C]pyruvate was 
not due to a switch to oxidative metabolism after treatment183. That hyperpolarised [1-
13C]pyruvate can detect changes in glycolytic flux, but not [18F]FDG, is a reflection that 
the rate of exchange between pyruvate and lactate is partly dependent on the lactate 
concentration which is determined primarily by glycolytic flux whereas the 
accumulation of [18F]FDG is only dependent on transport and phosphorylation160.  
 In a previous study [18F]FDG uptake did not decrease in Colo205 and HT29 
xenografts following treatment with conatumumab, a monoclonal antibody targeting 
DR5 (the same target as MEDI3039), despite histological evidence of cell death and 
99mTc-duramycin SPECT detection of phosphatidylethanolamine externalisation 




to treatment to the “metabolic flare” effect, which has been reported in several small 
case studies190. In metastatic colorectal carcinoma, four patients with increased 
[18F]FDG uptake in liver metastases one-two weeks after 5-fluorouracil treatment had 
the lowest [18F]FDG uptake after four-five weeks239. Similar observations have been 
reported in breast cancer, where a metabolic flare following initiation of tamoxifen 
treatment was predictive of response to treatment89. The attribution of this effect to 
macrophage infiltration and activation is based on the work of Kubota et al. who used 
micro-autoradiography to demonstrate that [18F]FDG in uptake is relatively higher in 
macrophages and granulation tissue87. However, they also concluded, “these findings 
do not mean that the inflammatory cells are the major source of radioactivity of 
[18F]FDG in tumour tissue. Despite more active uptake of [18F]FDG by inflammatory 
cells within or around the tumour, it is reasonable to consider that most of the 
radioactivity of [18F]FDG the whole tumour originates from viable tumour cells because 
they consist of the major component of the tumour mass87.” By using FACS to sort 
labelled populations we were able to quantify the [18F]FDG uptake per cell. We defined 
a phagocytic population as CD45+ and CD11b+, presumed in tumours to be mostly 
macrophages240. The majority of the CD11b+ population was also positive for 
mStrawberry+, both before and after treatment, indicative of tumour cell phagocytosis. 
Although macrophages were the most glycolytically active cell type, their low numbers 
meant that the majority of [18F]FDG] in the tumour accumulated in tumour cells, 
corroborating the findings of Kubota et al.87. In these tumours this excluded 
inflammatory infiltration and activation as a cause of “metabolic flare” and the failure 
of [18F]FDG to detect treatment response. An obvious limitation of this study is the use 
of subcutaneous human xenografts in mice with greatly reduced numbers of T-cells241. 




tumours which is similar to the numbers found in most early human colorectal 
tumours242. In a minority of human colorectal tumours, macrophages represent greater 
than 10% of the total cells which could potentially lead to higher proportional uptake 




 This study shows that hyperpolarised [1-13C]pyruvate MRI can be used for the 
early detection of cell death after treatment with changes in lactate labelling preceding 
a reduction in tumour volume, whereas no response to treatment was detected with 
[18F]FDG-PET. Furthermore, these experiments showed that [18F]FDG-6-P 
accumulation in tumours does not necessarily reflect glycolytic flux and that the failure 
of [18F]FDG-PET to detect treatment response could not be attributed to inflammatory 
cell infiltration or a “metabolic flare” effect.
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7.1. Summary of results 
• The [18F]FDG tumour-to-background ratio continued to increase beyond 60 min 
post-injection in subcutaneous tumours whereas in autochthonous Eµ-Myc 
tumours uptake reached a maximum after approximately 60 min. 
• Fasting mice prior to imaging enhanced tumour [18F]FDG uptake and 
suppressed myocardial uptake.  
• In EL4 murine lymphomas, etoposide treatment reduced [18F]FDG uptake and 
GLUT1 and GLUT3 expression. An inconsistent change in labelled 
lactate/pyruvate ratio reflected variable levels of cell death and no significant 
change in MCT1 and MCT4 expression, LDH activity or PARP cleavage.  
• In Eµ-Myc mice tumour volume, [18F]FDG SUV and labelled lactate/pyruvate 
ratio all decreased similarly following treatment with cyclophosphamide but also 
decreased in untreated mice. Hyperpolarised [1-13C]pyruvate improved tumour 
specificity compared to [18F]FDG.  
• In Colo205 and MDA-MB-231 tumours treated with MEDI3039, labelled 
lactate/pyruvate ratio and bioluminescence decreased prior to a decrease in 
tumour volume. This change was accompanied by a large increase in cell death 
and PARP cleavage and a decrease in MCT1 and MCT4 expression.  
• MEDI3039 treatment resulted in a relatively small decrease in [18F]FDG uptake 
in MDA-MB-231 tumours and no decrease in Colo205 tumours despite a 
reduction in GLUT1 and GLUT3 expression.  
• In Colo205 tumours the phosphorylation (and subsequent trapping) of [18F]FDG 
did not change after treatment, despite there being a significant reduction in 




• The most [18F]FDG-avid cells in Colo205 tumours were phagocytes although 
their low numbers meant that the majority of total uptake occurs into tumour 
cells. The high uptake of phagocytes did not contribute to the lack of treatment 
response seen using [18F]FDG-PET.  
 
7.2. Discussion 
 Anatomical imaging is essential in clinical practice to diagnose, stage, 
determine therapeutic strategy and monitor treatment response. However, it is 
becoming increasingly apparent that, for further improvements in outcomes to be 
made, knowing the site and spread of a tumour is insufficient and understanding and 
targeting individual tumour biology is required. Uniquely, molecular imaging can 
spatially map functional information providing a macroscopic understanding of 
tumours not possible using circulating biomarkers or biopsy-derived tissue. Delays in 
detecting tumour responses to treatment result in significant morbidity, delay switching 
to alternative therapy and result in prolonged use of increasingly expensive drugs. As 
molecular changes occur prior to changes in volume, molecular imaging has great 
potential for early detection of tumour response to treatment as already demonstrated 
clinically using [18F]FDG83, 84. 
The first uses of hyperpolarised [1-13C]pyruvate to monitor response to 
treatment in prostate cancer patients have yielded positive results110, 165. The aim of 
this study was to compare hyperpolarised [1-13C]pyruvate with [18F]FDG-PET for 
detecting tumour responses to treatment. The increased specificity of [1-13C]pyruvate 
for the Warburg effect may yield improved sensitivity of treatment response and also 
improve imaging of tumours in organs with high background uptake of [18F]FDG e.g., 




demonstrating a decrease in label exchange between hyperpolarised [1-13C]pyruvate 
and endogenous lactate in tumours following treatment (Table 1.3), studies that have 
compared the technique to [18F]FDG-PET have failed to demonstrate superiority69, 173. 
In the first study a reduction in [18F]FDG uptake preceded a reduction in pyruvate to 
lactate label flux, while in the other study tumour volume was better indicator of 
response than either molecular imaging technique69, 173. Here we demonstrated that 
hyperpolarised [1-13C]pyruvate and lactate can be imaged in vivo in 3D at high spatial 
and temporal resolution, although the investigation of intra-tumoral heterogeneity was 
precluded by the low per-voxel signal-to-noise ratio requiring signal averaging over 
the whole tumour for robust analysis149, 221. Four different tumour models treated with 
three different chemotherapeutics and imaged with [1-13C]pyruvate and [18F]FDG 
produced three different results. A reduction in [18F]FDG SUV and tumour volume was 
seen in EL4 tumours treated with etoposide, hyperpolarised [1-13C]pyruvate detected 
responses of Colo205 and MDA-MB-231 tumours to MEDI3039 and all three 
modalities detected responses of Eµ-Myc tumours to cyclophosphamide. The variable 
effect of treatment on imaging with [18F]FDG and [1-13C]pyruvate clearly indicates that, 
in cells undergoing drug-induced apoptosis, glycolysis is not globally inhibited but 
affected reactions are probably specific to the administered drug (although the 
contributions of tumour type and mouse breed may also contribute to the variation 
observed)243. [18F]FDG and [1-13C]pyruvate measure components of a common 
pathway but they measure separate reactions and neither is a surrogate for total 
glycolysis. [18F]FDG measures uptake and phosphorylation and does not report on the 
subsequent metabolism of glucose-6-P which, in addition to conversion to pyruvate, 
can enter the PPP, the glycogen synthesis pathway or numerous other pathways via 




downstream of hexokinase is highlighted by the experiments in Colo205 tumours 
treated with MEDI3039 where [18F]FDG-6-P continued to accumulate despite an 
almost complete inhibition of further glucose metabolism. In this instance the reduction 
in tumour lactate concentration and MCT1 and MCT4 expression meant that 
hyperpolarised [1-13C]pyruvate was a more sensitive marker of treatment response 
than [18F]FDG. In EL4 tumours where the predominant effect of treatment on glycolysis 
was to reduce GLUT1 and GLUT3 expression, [18F]FDG was the more sensitive 
marker of response. Although the relationship between irreversible [18F]FDG uptake 
and GLUT expression is complex, as demonstrated in Colo205 tumours treated with 
MEDI3039 where a reduction in GLUT expression did not result in a reduction in 
[18F]FDG uptake, in EL4 tumours a correlation has been demonstrated in two separate 
studies67, 69. The variable response seen with hyperpolarised [1-13C]pyruvate in EL4 
tumours was attributed to the variable levels of pre-treatment cell death which also 
has potential clinical relevance as human tumours have variable levels of pre-existing 
necrosis244.  
The studies reported in Chapters 2 and 4 demonstrate the importance of 
rigorous experimental design. Understanding the impact of animal handling is 
essential for pre-clinical imaging to avoid potentially false conclusions. Fasting and 
isoflurane anaesthesia have been shown previously to reduce background [18F]FDG 
uptake and this study corroborated these findings and also showed that fasting 
enhances tumour uptake187. In many cases sub-optimal imaging is sufficient as, 
particularly in clinical imaging, [18F]FDG imaging is only used for lesion detection. 
However, in Eµ-Myc cervical tumours [18F]FDG uptake by tissues adjacent to the 
tumour had a significant impact on interpretation that could be minimised by 




tumours may be possible using dynamic imaging or performing static scans at later 
time points199-203. 
The results presented here demonstrate the potential power of combining 
[18F]FDG-PET and hyperpolarised [1-13C]pyruvate MR imaging to measure multiple 
steps of glycolysis. Either modality alone would have only detected a response to 
treatment in three of four tumour types whereas combined imaging detected 
responses in all tumours. The conversion of hyperpolarised [U-2H, U-13C]glucose to 
lactate reflects flux through the entire glycolytic pathway which, theoretically, would 
also have detected responses to treatment in all models and could therefore be a 
single assay for data obtainable by combining [18F]FDG and hyperpolarised [1-
13C]pyruvate. However, clinical translation of hyperpolarised [U-2H, U-13C]glucose is 
currently limited by its short T1 and low polarisation119. Despite the possible 
improvements in hyperpolarised MRI, hybrid PET/MR systems may offer the best of 
both worlds: tumour and metastasis identification using the unrivalled sensitivity of 
[18F]FDG and 1H MRI and the ability to further characterise identified lesions with one 
or more hyperpolarised substrates in a single imaging session245. Functional 1H MR 
imaging has also shown the potential to detect tumour responses to treatment earlier 
than volume measurements. For example, diffusion weighted imaging (DWI) and an 
is a routine part of MR assessment of many tumour types and has demonstrated 
efficacy as a biomarker of response to a wide range of treatments with changes usually 
preceding decreases in tumour volume246, 247. The mono-exponential apparent 
diffusion coefficient (ADC) is the simplest and most frequently used mathematical 
model applied to DWI images to semi-quantitatively describe the diffusion 
characteristics of tissues. In the vast majority of cases tumour ADC increases following 




death and a relative increase in the interstitial water volume248. However, immediately 
post-treatment a transient decrease in ADC has also been observed which may be 
due to the converse effects of cytotoxic oedema, inflammation and fibrosis249.  
Hybrid PET/MR facilitates clinical comparison of hyperpolarised substrates, 
PET tracers and multi-parametric 1H-MRI in a single imaging session250. This has been 
demonstrated in rats with in a clinical PET/MR system where the ADC correlated with 
measurements of [18F]FDG uptake (SUV and total lesion glycolysis) but not 
measurements of [1-13C]pyruvate metabolism (kPL and AUC), the discrepancy being 
attributed to the low spatial resolution of 13C chemical shift imaging and the limited 
numbers in the study251. In a separate study EL4 murine lymphomas treated with a 
vascular disrupting agent, changes in [1-13C]pyruvate and 1,4-13C2]fumarate 
metabolism were demonstrated at 6 h post-treatment whereas reductions in the ADC 
were not observed until 24 h post-treatment167. However, DWI is also an evolving field 
and earlier and more accurate detection of response to treatment than is possible with 
ADC has been reported in patients using more complex modelling of DWI, for example 
using IVIM (intravascular incoherent motion) and VERDICT (Vascular, Extracellular 
and Restricted Diffusion for Cytometry in Tumours), although the former has produced 
inconsistent results particularly in prostate cancer252, 253.  
The capability of hyperpolarised imaging to provide novel insights into tumour 
metabolism in vivo is unrivalled which, as well as improving our understanding of 
tumour biology, has great potential to identify novel therapeutic targets and potentially 
be introduced as a companion diagnostic. However, several barriers to clinical 
translation still exist.  
Further technical development, primarily focussed on improving the signal-to-




progress made in the last decade. The hyperpolarised signal that is initially available 
can be increased by increasing the level of polarisation (which has already been 
improved considerably by using the latest generation of polarisers105), improved and 
faster injection protocols and increased probe concentrations. Annihilation of the free 
radical and removal of gadolinium ions following polarisation would substantially 
increase the pre-injection T1 and, along with the increasing clinical evidence that 
injection of hyperpolarised substrates is safe111, may also help to relax the stringent 
and time consuming quality control practices currently employed254, 255. Following 
injection, improvements in the hardware and sequence design can help preserve and 
take advantage of the available signal. These include increasing the magnetic field 
and gradient strengths and improving the 13C coil design to permit uniform sensitivity 
over larger volumes and parallel acquisition to reduce the number of phase encoding 
steps required256. From the first studies that employed spectroscopy and single time-
point chemical shift imaging107, sequences have already improved considerably to 
both increase spatial and temporal resolution whilst minimising substrate excitation to 
preserve the available signal. Numerous sequences that rapidly acquire 3D spatial, 
temporal and spectral data whilst maximising signal-to-noise have been developed 
using spectral-spatial and spectroscopic echo-planar and spiral imaging149, 221, 256, 257, 
balanced steady state free precession150, 258, and indirect detection by polarisation 
transfer from 13C to 1H nuclei153. So far, 13C echo-planar spectroscopic imaging (EPSI) 
has been the most widely used in human studies largely due to being less prone to 
artefacts and less demanding on gradients than spiral acquisitions and more reliable 
at low field strength than spectral-spatial excitation257. Improvements in image 
reconstruction, potentially through the use of compressed sensing, also have great 




which leads to preservation of hyperpolarisation and increases in the available 
signal259.  
Assuming that sufficient signal-to-noise ratio can be achieved there are several 
questions to be answered prior to hyperpolarised imaging becoming part of routine 
clinical practice. The repeatability of hyperpolarised in pre-clinical imaging has been 
demonstrated in pre-clinical studies of tumours and normal tissue233, 260. Sufficient 
repeatability in human studies to permit accurate differentiation of normal and 
pathological tissue and reproducibility across multiple sites is an important goal for the 
early clinical studies256. Comparisons between hyperpolarised imaging, current state-
of-the-art imaging techniques (including [18F]FDG-PET and multi-parametric 1H MRI) 
and histological classifiers can be incorporated into repeatability studies to build on 
the proof-of-concept studies already performed110, 111, 261 and, ultimately, these initial 
trials should begin to answer the critical question of whether hyperpolarised MRI can 
provide novel information that can guide clinical decision making256.  
 
7.3. Conclusions 
 [18F]FDG-PET and hyperpolarised [1-13C]pyruvate were used to detect the 
response of four tumour models to treatment with three different chemotherapy drugs. 
In human colorectal and breast adenocarcinoma models a reduction in lactate 
labelling following injection of hyperpolarised [1-13C]pyruvate detected cell death prior 
to a reduction in tumour volume when [18F]FDG-PET did not detect a response. 
However, in EL4 tumours where cell death was variable before and after treatment, 
[18F]FDG and tumour volume measurements detected a response to etoposide 
treatment whereas there was no significant change in labelled lactate/pyruvate ratio. 




proportionally, although the response of these lymphomas was not necessarily due to 
the drug. Despite the discrepancies between tumour models and drug treatments, 
combined imaging with [18F]FDG and hyperpolarised [1-13C]pyruvate imaging 
detected responses in all tumours, providing a persuasive argument for evaluation of 
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